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Abstract 
This minor dissertation investigates alternative compulsory licencing (CL) policy 
approaches for the South African context. The purpose is to support the country’s aspirations 
to reform certain components of its intellectual property (IP) regime, ensuring alignment with 
the country’s development prerogatives. Homing in on technical barriers with the 
operationalisation of the existing CL mechanism; this paper investigates remedial 
recommendations to support South Africa’s reform efforts. The paper also hopes to gauge 
whether it is feasible to leverage compulsory licensure as a cost-containment tool to circumvent 
price dominance in the sale of essential pharmaceutical commodities.  
The South African Patents Law provides for CL under three grounds. These are dealt 
with in chapter 2. The abuse of patents rights as a result of excessive pricing is one of these 
grounds. Yet, attempting to use this provision abuse of patents rights is procedurally and 
administratively cumbersome. This is notwithstanding the litigation costs. The 2018 national 
IP Policy aspires to reform the CL policy to ensure that it is a ‘workable mechanism’.  
A comparative analysis of the CL policy landscapes in the People’s Republic of China 
(PRC) and the Russian Federation will be taken to inform South Africa’s discourse. These two 
countries are strategic because they have either reformed and/ or in the process of renovating 
their intellectual property rights (IPR) landscapes and both have interesting approaches to the 
way in which they have reformed their CL mechanisms. 
The findings of this paper reveal that Russia and China have undertaken extensive IPR 
reforms over the last three decades. They have both taken different policy approaches in 
adapting their CL instruments. Russia’s CL reform proposals are underway and aim to advance 
a CL mechanism that can effectively regulate the abuse of patents, especially for essential 
pharmaceutical commodities. China has installed specific Implementing Measures which offer 
policy guidance on the applicability CLs. In the case study of China, the Measures imposed are 
not necessarily advanced as cost-containment tools. Rather they support the country’s 
pharmaceutical  agenda. The recommendations in this paper offer interesting insights to the 
feasibility exercises that will be advanced in South Africa’s IPR reform process. 
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Chapter 1: Introduction 
The basic rationale underlying patent protection is to safeguard the inventor’s rights 
from unfair exploitation. This is achieved by granting patent licenses to investors, thereby 
affording them exclusivity to dictate the parameters for the sale, use and distribution of their 
inventions. This also protects them from abuse of their rights as related to these inventions.1 In 
exchange, the inventor is required to disclose their invention for the public interest. Conversely, 
if there is an abuse of a patent right by an inventor, the law provides parameters for recourse to 
aggrieved parties. This is essentially the quid pro quo of intellectual property theory.2  
The World Trade Organization’s (WTO) Agreement on Trade Related-Aspects of 
Intellectual Property Rights (TRIPS Agreement) has enforced non-discriminatory patentability 
of products and processes, including essential pharmaceuticals. As a result of the global patent 
system, competitive bidding on a patented product is not always a viable option, unless said 
patent is deemed ineffective or the protection period lapses. Many developing and developed 
countries have realised the limitations of leaning only on voluntary licensing and their 
competition laws, as tools to control the price of essential pharmaceuticals. While many still 
have low local pharmaceutical manufacturing capacity. In a 2016 assessment of the state of 
manufacturing in the African region, Ngozana et al note the unremitting constraints faced by 
all African member states due to pharmaceutical expenditure. The burgeoning local 
pharmaceutical industries in the region required  policy preparedness in order to regulate the 
cost issues that will arise with the growth of local manufacturing.3  
Installation of compulsory licensure as part and parcel of other cost-containment 
measures could be another alternative to regulate price controls in the pharmaceutical sector. 
 
 
1 According to the South Africa Patent Act no. 57 of 1978 (and related amendments); a "patent" means letters 
patent for an invention granted in the Republic; (xiv) and a ''patented article" means any article in respect of 
which a patent has been granted and is for the time being in force; (vi). Available at Available at 
https://www.gov.za/documents/patents-act-9-apr-2015-0827, accessed 18 June 2019. 
2 Yousuf A Vawda 'Compulsory Licensing Jurisprudence in South Africa: Do we have our priorities right' 
available at https://www.southcentre.int/wp-content/uploads/2018/12/RP90_Compulsory-Licensing- 
Jurisprudence-in-South-Africa-Do-We-Have-Our-Priorities-Right_EN-1.pdf, accessed on 17 June.2019. 3 
3 Skhumbuzo Ngozwana et al 'Policies to Control Prices of Medicines: Does the South African Experience 
Have Lessons for Other African Countries?' in Making Medicines in Africa London, Palgrave Macmillan (2016) 
203. 
A typical feature in the architecture of most patent systems, CL has had a long history.4 
The English Statute of Monopolies 1623 is one of the earliest legal instruments in which 
concept of compulsory licensing was incorporated.5 CL was later articulated under Article 
5A(2) and (4) of Paris Convention Paris Convention for the Protection of Industrial Property 
of 1883. Article 5A(2) provides that “each country of the Union shall have the right to take 
legislative measures in providing for the grant of compulsory licenses to prevent the abuses 
which might result from the exercise of the exclusive rights conferred by the patent, for 
example, failure to work.”6  It is worthy to note that during the World Wars, CL was resorted 
to, in order to promote sharing of aviation technology and the manufacture of penicillin.7 
Currently, CL is featured under international trade rules and customs as regulated by 
the TRIPS Agreement - the most comprehensive multilateral agreement on regulation and 
enforcement of intellectual property rights to date.8 This Agreement requires member states to 
adopt minimum standards of IP protection, including for pharmaceutical products and 
processes. The term ‘compulsory license’ does not expressly appear in the TRIPS Agreement. 
Instead the phrase; “other use without authorization of the right holder” appears under Article 
31.9 It provides for instances “where the law of a Member allows for other use of the subject 
matter of a patent without the authorization of the right holder, including use by the government 
or third parties authorized by the government…”  
Article 31 lays down conditions that govern the exploitation of CLs by WTO members. 
But the Agreement does not provide explicit guidance as to how member states should install 
and implement CL mechanisms. It mentions instances where these can be considered, including 
 
4 A ‘compulsory license’ or otherwise referred to a ‘non-voluntary license’ is an authorisation given by a national 
authority to a person, without or against the consent of the title holder, for the exploitation of a subject matter 
protected by a patent or other intellectual property rights. Please note that within this dissertation, the term will be 
spelled in accordance to the jurisdictions observed as part of the case studies observed herein. 
5 Abbas Muhammad Zaheer; Riaz Shamreeza 'Evolution of the concept of compulsory licensing: A critical 
analysis of key developments before and after TRIPS' (2013) 4 Academic Research International 484. 
6 Article 5A(2) Paris Convention for the Protection of Industrial Property of 1883 
7 Section 27 Discussion Paper, Compulsory Licensing (2010) available at https://section27.org.za/wp- 
content/uploads/2010/10/DIPPdiscussionPaper.pdf, accessed on June 2019. 
8 World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS Agreement), available at https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm (Accessed 3 March 
2019). The TRIPs came into effect on 1 January 1995, through the General Agreement on Tariffs and Trade 
(GATT) and is governed by the World Trade Organisation (herein ‘WTO’) 
9 TRIPS Agreement – Article 31 (Practice) WTO Analysis Index, Available at 
https://www.wto.org/english/res_e/publications_e/ai17_e/trips_art31_oth.pdf 
in cases of national emergencies, circumstances of extreme urgency, and/ or anti-competitive 
practices, as possible grounds for compulsory licensing.10   
After its adoption, WTO member states had an obligation to take incremental steps 
towards reforming their domestic laws to conform with this Agreement. The explosion of 
public health disasters such as HIV and AIDS called for urgent action by countries in 
controlling the epidemic. This included ensuring availability of essential patented medicines to 
the millions of citizens who were afflicted with the disease. Global level negotiations 
commenced to find remedies towards this access issues facing member states and the WTO 
requirement for member states to reform their domestic laws to align with the requirements of 
the global patent system. 
These negotiations culminated in the adoption of the Declaration on the Agreement on 
Trade Related Aspects of Intellectual Property Rights and Public Health (the Doha Declaration) 
on 14 November 2001 by member states to the WTO. 11  As a supplement to the TRIPS 
Agreement, this Declaration recognised that member states - especially Least Developed 
Countries (LDCs) and Developing Countries (DCs) - were at different stages of development. 
This as a result of, but not limited to, historical and political shortcomings; greatly impacting 
their economic development. It also recognises that many of these member states had limited 
or no industrialisation capacity to manufacture medicines locally. As a result, the Doha 
Declaration made certain flexibilities afforded by the TRIPS Agreement available to member 
states, to support them in navigating the international trade system.12  
The Declaration recognised that IP protection was important in the development of new 
medicines while raising concerns about the prices of patented essential pharmaceutical 
medicines. Article 5(b) of the Doha Declaration reaffirms that, “….while maintaining our 
commitments in the TRIPS Agreement, we recognize that…Each member has the right to grant 
compulsory licences and the freedom to determine the grounds upon which such licences are 
 
10 Eric W. Bond & Saggi Kamal 'Compulsory licensing, price controls, and access to patented foreign products' 
(2014) 109 Journal of Development Economics 3. 
11 World Trade Organisation (WTO) 'Declaration on the TRIPS and Public Health. DOHA WTO Ministerial 
2001: TRIPS WT/MIN(01)/DEC/2 (20 November 2001)' available at 
https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm, accessed on 30 December.2018. 
12 Article 4 of the Doha Declaration on the TRIPS and Public Health. TRIPS flexibilities: Measures that ‘allows 
governments to make exceptions to patent holders’ rights such as in national emergencies, anti-competitive 
practices, or if the right holder does not supply the invention, provided certain conditions are fulfilled. WTO 
Factsheet ‘TRIPS and Pharmaceutical Patents’ (September 2006), Available at 
http//www.wto.org/English/tratop_e/trips_e/factsheet_pharm02_e.htm#importing, accessed 3 August 2018. 
granted.”13 While Article 6 provide recognised that “WTO members with insufficient or no 
manufacturing capacities in the pharmaceutical sector could face difficulties in making 
effective use of compulsory licensing under the TRIPS Agreement.”14 The Council for TRIPS 
was instructed to find an expeditious solution to this problem and to report to the General 
Council before the end of 2002. This policy instrument accorded member states the green light 
to leverage compulsory licensure for their domestic needs. 
Background and context  
CLs are also covered under the South African patent law. The grant of CLs and the 
ground for grant of CLs are covered under Sections 55 – 56 in Chapter VIII of the Patents Act 
(and its related amendments).15 
Over the last three decades South Africa’s CL mechanism has attracted debate. The 
government has  never been granted CL to remedy abuse of patent rights or to circumvent anti-
competitive behaviour. Most of the criticisms levelled against the mechanism, have been on its 
rigidity. The adjudicatory procedure is considered prohibitive and inflexible. 16  Rather the 
country has leaned on the rules of competition law to remedy the abuse of patent rights and 
anti-competitive behaviour.17 
Policy makers acknowledge that there is misalignment in the country’s intellectual 
property Rights (IPR) regime, impacting amongst others domestic access to essential 
medicines. Pursuant to this imperative, the government announced its first comprehensive 
national IP Policy in 2018 (IP Policy).18 This policy recognises several shortcomings in the 
country’s current IPR regime. It observes that while South Africa’s IP and patent system is 
largely compliant with international trade law, some parts of the patent legislation remain 
incompatible in advancing the protectionist mandate of the IP law and policies. “Specifically, 
the intersection of IP and public health has long been an issue of contention within South 




15 Patents Act no. 57 of 1978 
16 Chan Park et al Using Law to Accelerate Treatment Access in South Africa: An Analysis of Patent, Competition 
and Medicines Law (2013) United Nations Development Programme (UNDP), available at 
https://hivlawcommission.org/wp-content/uploads/2017/06/Using-Law-to-Accelerate-Treatment-Access-in-
South-Africa-An-Analysis-of-Patent-Competition-and-Medicines-Law.pdf , at 57 (Accessed 29 September 2019) 
17 Competition Amendment Act No. 18 of 2018 
18 Ibid 
19 Ibid 
which will advance a holistic pro-public health IP landscape. It envisages an overhaul of some 
of key IP policy instruments and implementing measures; while reviewing and reforming some 
of the technical ambits of the provisions leveraged for the grant and opposition of patent 
licences. The IP Policy states that the country wishes to align its currently CL mechanism with 
the TRIPS Agreement in order to meet the country’s development objectives.20 
Purpose of the dissertation 
This thesis seeks to uncover the treatment of CL in the IP policy and legal landscapes 
of two counterparts - one in Asia and the other in Eastern Europe. The countries from which 
case studies are cultivated include the Russian Federation and the People’s Republic of China 
(PRC). The paper does this by undertaking a comparative study of the CL policy approaches 
and implementation models of these two countries as compared to the Republic of South 
Africa. This is to gauge whether the CL policy reform approaches by these countries operate 
in part, as cost-containment measures to regulate the abuse of patent rights, while promoting 
sustainable access to essential pharmaceutical commodities. Russia and China have rarely 
threatened to grant CL to remedy anti-competitive behaviour in the field of pharmaceuticals.  
The paper investigates whether it is possible to untangle South Africa’s overly 
formalistic CL mechanisms by learning from alternative policy perspectives. An assumption is 
made that the CL mechanism in South Africa is currently not being sufficiently leveraged as a 
cost-containment mechanism and as a flexibility under the TRIPS Agreement. 
Russia and China were selected as case studies because both countries boast similar 
developmental imperatives to South Africa. Previous offerings have focused heavily on CL 
approaches in India and Brazil and less so on China and Russia. It is acknowledged that the 
legal systems of these counterparts differ, both witness enormous political and economic 
transitions in in the 1990s. What is interesting is that China and Russia have taken different 
approaches in developing their domestic IPRs and Patent laws and policies. The evolution of 
their CL mechanisms over the last two decades have also been influenced by these three WTO 
member states’ obligations under the TRIPS and their domestic development agendas. 
All three countries boost neoliberal economic policy positions to as part of their 
strategies to integrate themselves into the global trade market, while advancing positions 
advantageous to their domestic growth plans. Russia and Chinese IPR regimes have adapted 
 
20 It is noted that the national IP Policy, 2018 does not define what a ‘workable’ compulsory mechanism means. 
their CL as tools to advance the liberalisation of their domestic pharmaceutical industries. This 
is a path that South Africa aspires to follow. 
As is shown in the table below, these three jurisdictions make provision for CLs in their patent 
laws. There are provisions for grant of CLs in the area of (i) non-working patents and (ii) for 
dependent patents. Only South Africa and China allow for CLs to remedy patent abuse. While 
Russia does not explicitly state this in their Patent legislation. Additionally, only China’s laws 
allow for grant of CL in the public interest. 
 
Structure of dissertation 
The study is broken up into five Chapters. The first Chapter explores the relationship 
between patent protection and the excessive pricing dilemma to accessing affordable 
pharmaceutical commodities. The Chapter offers a brief historical background of the history 
of CL and how these are articulated in the World Trade Organization’s (WTO) Agreement on 
Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement). It goes further to 
expand on CL as one of the flexibilities afforded to member states to leverage upon in certain 
scenarios through the adoption of the 2001 Doha Declaration on the TRIPS and Public Health. 
It then offers a snapshot of the treatment of CL in the South African context. It outlines the 
challenges with the current mechanism and the aspirations of the IP policy to install what the 
Countries Patent laws Provision of the Law 





















Patents Act No. Sections 55-56 of the Allowed / YES Allowed / YES Allowed / YES Not explicitly 
Africa 57 of 1978 (as last Patents Act No. 57 of    provided 
 amended by Act 1978 (as amended by     
 No. 58 of 2002) Act No. 58 of 2002)     
People’s 
Republic 
PRC Patent Law, Articles 48-58 of the Allowed / YES Allowed / YES Allowed / YES Allowed/ YES 
of China (PRC) 1984; (amended Patents Law of     
 in 1992, 2000, 12/03/1984 as last     
 and 2008) amended on     
  27/12/2008 and State     
  Intellectual Property     
  Office Order # 37 of     
  November 2005     
Russian Part IV of the Compulsory Allowed / YES Allowed/ YES Not explicitly Not explicitly 
Federation Civil Code Licensing is provided   provided provided 
 of the Russian for under Articles     
 Federation 1360 and 1362 of the     
 dictates Patents Patent Act (Chapter     
  72)     
IP policy notes as a ‘workable CL mechanism’ that will safeguard the country’s public health 
imperatives. 
The second Chapter focuses on the case study of the Republic of South Africa. It briefly 
outlines the post-1994 public health discourse and details some of the challenges faced in 
sustaining access to medicines for the country’s burgeoning communicable and non- 
communicable disease burdens. The Chapter then outlines the evolution of the IPR and patent 
landscape since South Africa acceded to the WTO and the strides that have been made since 
then. The treatment of CL in the policy landscape and in jurisprudence is a key focus. It also 
highlights how competition law has formed the backbone of the challenging matters related to 
excessive pricing and the abuse of patents. The intersection between patent and competition 
law is briefly discussed, as the latter is often exploited to address abuse of patents in medicines 
pricing. Lastly, the Chapter provides an appraisal of the recent policy proposals to reform the 
current CL mechanism as articulated in the national IP policy. 
The third Chapter follows a similar pattern as the second one. The offering reviews this 
country’s public health transitions post-Soviet collapse and effects of that system. The Chapter 
then reviews how Russia’s accession to the WTO influenced the adaptation of its IPR 
landscape. It then explores the policy approaches and evolving role of the CL mechanism in 
the numerous amendments that have been made to its IPR regime. It advances a brief outline 
of the recent proposals by various national bodies to reform the CL mechanism and to advance 
a protectionist safeguard to the public interest and as a cost-containment tool to advance access 
to affordable pharmaceuticals. The Chapter concludes by providing an overview of current 
policy debates around the best policy approaches to advance CLs.  
The fourth Chapter delves into the People’s Republic of China (PRC) as a case study. 
It follows a similar trajectory as the previous two chapters. Firstly, by laying out an overview 
of the evolution of the health care system. It reviews the PRC’s IPR landscape, including 
various amendments that have been made to its Patent laws before and after its accession to the 
WTO in 2001. The journey of how this country has approached compulsory licensure both in 
law and policy is provided to illustrate the precision with which this counterpart has tried to 
carefully articulate CL through installing specific CL measures. The Chapter concludes by 
evaluating whether advancements in the PRC are worth considering for the South African 
discourse. 
Chapter five provides a summary of the concluding observations on this subject matter. 
It distils the key lessons and approaches followed by Russia and China in adapting their IPR 
regime to inform their developmental imperatives of their national contexts. The Chapter offers 


















Chapter 2: The Republic of South Africa: Evolution of IPR framework and treatment of 
compulsory licensure 
The purpose of this Chapter is provide an overview of South Africa’s public health 
landscape and to review the  existing IPR regime and patents architecture. The outline of the 
Chapter is as follows: (i) An overview of the public healthcare sector to appreciate the 
challenges faced in the country’s efforts to advance an equitable health system that is able to 
address the burgeoning communicable and non-communicable public health disease burdens. 
This requires securing access to innovative and sustainable pharmaceutical commodities. (ii) 
The IPR legislative framework is discussed, including an overview of the regulatory reforms 
to align the current system to the TRIPS Agreement and the Doha Declaration. (iii) An analysis 
the country’s CL mechanism is undertaken to distil the existing challenges. The offering will 
also look at reliance on competition law as the proffered regulatory solution in matters related 
to excessive pricing of pharmaceutical products. (iv) A conclusion will be drawn about the 
reform proposals and processes that the country is about to embark upon to reform its IPR 
regime and the CL mechanism. 
Overview of the public health landscape 
An overview of South Africa’s public healthcare architecture reveals that efforts 
undertaken by the post-1994 government in this area of concern, were not only to remedy the 
policy incoherence as a result of the policies of its predecessor; but also to address the highly 
fragmented and bureaucratic health care system inherited from the pre-1994 government.21 
During this period, neoliberal economic policies were advanced to integrate South Africa into 
the international markets space.22 Since then, the country continues to experience a solid geo-
political footprint.  
In terms of public health, South Africa operates on a two-tiered health care delivery 
system – a private and public sector. These two tiers account for disparate health care 
resourcing while the delivery of health care services differs substantially. The private 
healthcare sector caters to an estimated 16% of the population (7 million people). This market 
has access to medical insurance through medical aid schemes, access to private hospitals and 
 
21  Melody Brauns Public Healthcare in a post-Apartheid South Africa: A Critical Analysis in Governance 
Practices, The University of Kwazulu-Natal, South Africa, 2016) 170. 29 
22 Mickey Chopra et al 'Achieving the health Millennium Development Goals for South Africa: challenges and 
priorities' (2009) 374 The Lancet 1027. 
therefore high-quality private healthcare.23 While the public healthcare sector caters for the 
healthcare needs of 84% of the population (42 million people).24 
          The post-1994 government commenced a major overhaul of the public health system to 
align with the country’s new democratic reality. This was achieved through enacting numerous 
progressive legislative and policy measures. These frameworks guided the realisation of equal 
access to quality healthcare. This included the articulation of the right to access to healthcare, 
food, water and social security under section 27 of the Constitution of the Republic of South 
Africa.25 
Following on this Constitutional decree, implementation regulations were introduced 
to effect functional public health care system. The National Health Act (NHA) 61 of 2003 was 
regarded as the fundamental legislative framework for health care delivery in South Africa, 
replacing all previous health policies. 26  In addition to the NHA providing the legislative 
framework for the overall health system, several other acts focused on regulating different  
dimensions of the public health system. Other significant legislative advancements since 1994 
focus on strengthening the regulation of medical schemes, the establishment of the National 
Health Laboratory Service (NHLS) and taking steps to improve access to medicines.27 
The progress made in terms of reforming the public health system was overshadowed 
by the explosion of HIV/AIDS and the emergence of multi-drug resistant and extensively drug-
resistant Tuberculosis (MDR and XDR‐TB).28 The increase of non-communicable diseases 
continues to place an additional responsibility on an already burdened and underdeveloped 
public healthcare delivery system struggling to overcome poor administrative management, 
 
23 The private healthcare sector accounts for R33.2 billion of pharmaceutical expenditure which equates to 84% 
of total pharmaceutical spend in the country. Accessed from Organisation for Economic Co-operation and 
Development, ‘Excessive Pricing in Pharmaceutical Markets – Note by South Africa’ 
DAF/COMP/WD(2018)117, available at https://one.oecd.org/document/DAF/COMP/WD(2018)117/en/pdf 
accessed 23 June 2019 at 2. 
24 Ngozwana et al, 203. 
25 Section 27 of the Constitution of the Republic of South Africa Act 108 of 1996 
26 Ibid 
27 Di McIntyre & John Ataguba Access to quality health care in South Africa: Is the health sector contributing to 
addressing the inequality challenge? (2017) University of Cape Town, available at 
https://www.parliament.gov.za/storage/app/media/Pages/2017/october/High_Level_Panel/Commissioned_report
s_for_triple_challenges_of_poverty_unemployment_and_inequality/Diagnostic_Report_on_Access_to_Quality
_Healthcare.pdf, accessed on 18 July 2019. 3 
28Graham S. Cooke, R. Kate Beaton et al, ‘International Spread of MDR TB from Tugela Ferry, South Africa’ 2011 Nov; 
17(11): 2035–2037. National Center for Biotechnology Information. Available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310562/  
low morale and lack of funding.29 Three decades later and the South African public health 
system remains in state of developmental flux. 
An area which continues to undermine the government’s efforts at deriving a policy 
landscape to ensure an equitable and equal health remains allocative efficiency, which is 
derived from affordability of health care services.30 To remedy these prevailing systematic 
challenges, the South Africa continues to implement public health policy reforms efforts. Since 
2012 the Ministry of Health has been extensively engaged in effecting a systematic overhaul 
of its healthcare system to realise equitable and equal national healthcare coverage. It is 
envisaged that the implementation of a National Health Insurance (NHI) will not only reduce 
the costs of essential health commodities but will result in national health coverage.31 The NHI 
is currently being piloted in some provinces of South Africa.32 While the inner mechanisms of 
the implementation of the NHI do not form the subject matter of this paper, the affordability 
and accessibility dimension of the pharmaceutical allocative efficiencies are summarised in the 
discussion below. 
Sustaining access to affordable pharmaceutical medicines 
Accessibility and affordability to products and processes, including pharmaceutical 
commodities such as medicines, is largely driven by policy and regulatory considerations. Price 
- a regulatory issue - is one of these, while supply and demand are subject to economic and 
market dynamics. The delivery of pharmaceutical commodities is relational requiring complex 
interactions and negotiations between governments and industry players who hold the 
monopoly on these commodities. The regulation of medicines is governed by the Medicines 
and Related Substances Control Act (101 of 1965), which came into effect in 1967. 
Within the South African context, access to pharmaceuticals contributed greatly to the 
disparities in the country’s two-tiered health care system. It is noted that pre-1994, the pricing 
of medicine was largely subject to market forces, with the result that multinational 
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32 Department of Health Republic of South Africa Status of NHI Pilot districts (2015) available at 
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pdf . Accessed on 29 July 2019. 
pharmaceutical companies were free to determine the price at which they sold their products 
in the country.33 This landscape allowed pharmaceutical companies to set their products at 
prices that they deemed appropriate and engaged in marketing tactics which incentivise and 
encourage the dispensing of their products. This resulted in innovator brands dominating the 
market and essentially limited generics market share. In addition, pharmaceutical companies 
were able to discriminate amongst clients based on volume purchases and other 
considerations.34 
South Africa has implemented several important medicine pricing interventions in the 
post- apartheid era, informed by the 1996 National Drug Policy.35 This policy sought to level 
the playing field by increasing access to safe, affordable and quality medicines for all South 
Africans. It laid the foundation for subsequent revisions to legislation and regulations to reduce 
prices and improve access to pharmaceutical products. The objectives of this policy are 
described below in Table 1.36 
 
This policy led to an overhaul of the national health legislation. Amendments to 
legislation in 1997, resulted in the promulgation of the Medicines and Related Substances 
Control Amendment Act.37 This Act amended the Medicines and Related Substances Control 
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35 Department of Health National Drug Policy for South Africa (1996) available at 
https://www.gov.za/sites/default/files/gcis_document/201409/drugpol0.pdf, accessed on 22 June 2019. 
36 Andy Gray et al 'South Africa’s National Drug Policy: 20 years and still going?' available at 
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Amendment Act of 1991,38 the Health and Welfare Matters Second Amendment Act 180 of 
1993, the Pharmacy Act 53 of 1974, the Medical, Dental and Supplementary Health Service 
Professions Act 56 of 1974 and the Allied health Professions Act 63 of 1982. 
These amendments resulted in a significant shift in the pharmaceutical products 
landscape, including in the way these products were supplied and marketed in South Africa. It 
also made provision for the importation of medicines by companies other than the patent 
holder, prohibited sampling medicines, bonuses, rebates and any other incentives and made the 
generic substitution of products mandatory.39  The most controversial amendment was the 
incorporation of section 15C of the Act, which provided for “Measures to ensure supply of 
more affordable medicines”. This will be dealt with later in the Chapter. 
Other structural interventions required by the Act was the establishment of a Pricing 
Committee under section 22G (1). This Committee was tasked with rectifying the price 
distortions in the market by developing a transparent pricing system for all medicines and 
scheduled substances sold in the country.40 As a result, a Single Exit Price (SEP) regulatory 
framework was introduced in 2004. Under the SEP regime, the price at which manufacturers 
sell to pharmacies is regulated and cannot be varied according to volume sold.41 The Minister 
of Health is tasked with determining the extent to which the SEP may be adjusted after 
considering the recommendations of the Pricing Committee. This price adjustment is subject 
to inflation and the need to ensure the availability, affordability and quality of medicines in the 
country. 
These reforms contributed towards a substantial decrease in the price of medicines 
including HIV treatment. These efforts resulted in price reduction of first line anti-retroviral 
(ARV) regimens by 96% since 2000, resulting in access to generic lifesaving medicines.42 By 
2004, the prices offered by companies for triple therapy in South Africa have fallen from the 
initial patented price of approximately US$10,000 per patient per year to approximately 
US$1000, as a result of competition. Even with this price reduction, generic companies such 
as Aurobindo, an Indian generic company, were offering triple-therapy regimen for US$295 
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42 Catherine Tomlinson et al Patent barriers to medicine access in South Africa: A case for patent law reform 
(2016) available at http://www.fixthepatentlaws.org/wp-content/uploads/2016/09/MSF-FTPL-report-FINAL- 
VERSION.pdf, 8 
per person per year.43 A decade after the introduction of the SEP, total spending on patented 
drugs totalled R22.12 billion in 2014, whereas spending on generic drugs totalled R12.85 
billion in the same year. This clearly shows a R10 billion odd reduction in the price of generic 
essential drugs.44 
It is observed that there have been criticisms levelled against the SEP framework in the 
last decade. The most vocal being that these the limit price negotiation and as a result reduced 
price competition particularly for innovative medicines where no generic alternatives are 
available.45 Secondly, that the Minister of Health operating through the Pricing Committee, 
determines an annual percentage increase of SEP that is uniformly applied to all products. Yet, 
this is one of the most transparent mechanisms that consumers have at their disposal to monitor 
medicines procurement processes. Consumers can access the access SEP information from the 
South African Medicine Price Registry.46 
A key intervention of the National Strategic Plan (NSP) on HIV, STIs and TB (2012 – 
2016) was ensuring access to affordable, high-quality drugs to treat HIV, sexually transmitted 
infections (STIs) and tuberculosis (TB). It further identified the cost of ARVs being the single 
greatest expenditure in the NSP’s budget.47 The recent National Strategic Plan (NSP) on HIV, 
STIs and TB (2017-2022) has identified the scale up of treatment access for all diseases, as a 
key priority. 48  The country’s commitment to increasing access to essential medicines for 
communicable and non-communicable diseases, are fortified by the aspirations of the national 
IP Policy and reform of the patents system is seen as a strategic imperative to safeguard its 
public health priorities. 
Overview of the IPR legislative framework in South Africa and obligations under the 
TRIPS Agreement 
The Republic of South Africa has enjoyed an elaborate and long-established system of IPRs, 
just like the rest of the African countries who were colonised. As South Africa was colonised 
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47  South African National AIDS Council National Strategic Plan on HIV, STIs and TB 2012–2016 (2012) 
available at http://www.doh.gov.za/docs/stratdocs/2012/NSPfull.pdf, accessed on 12 September 2018. 
48 South African National AIDS Council South Africa’s National Strategic Plan for HIV, TB and STIs 2017- 2022 
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accessed on 14 September 2018. 
by the British, the Cape Colony and the Natal Colony enacted their own patent statutes, these 
were British IPR rules. In England the Statute of Monopolies of 1623 swept away all 
monopolies except those made by the “true and first inventor” of a “method of manufacture.”49 
The Constitution of the Republic of South Africa remains the highest law of the land.50 The 
spirit of promoting equality and equity in health care services was clearly and boldly articulated 
under section 27 of the Constitution of the Republic of South Africa Act 108 of 1996.51  
The section states: 
27(1)“Everyone has the right to have access to; 
a. health care services, including reproductive health care 
b. sufficient food and water; and 
c. social security, including, if they are unable to support themselves and their 
dependents, appropriate social assistance. 
2) The state must take reasonable legislative and other measures, within its available 
resources, to achieve the progressive realisation of each of these rights 
3) No one may be refused emergency medical treatment.” 
Sections 25(1) and 4(b) of the Constitution do provide for the protection of property but do 
not expressly mention IP. Section 25(1) provides that “No one may be deprived of property 
except in terms of law of general application, and no law may permit arbitrary deprivation of 
property.” While section 25 (4) (b) provides that for the purposes of this section, “property is 
not limited to land”. 
The country boasts a comprehensive IPR architecture. These are governed and protected 
by the common law and regulated through the following pieces of legislation: the Patents Act 
57 of 1978; Trade Marks Act 194 of 1993; Designs Act 195 of 1993; Copyright Act 98 of 1978; 
Plant Breeders’ Rights Act 15 of 1976; Merchandise Marks and Counterfeit Goods Act 17 of 
1941; Intellectual Property Rights from Publicly Financed Research and Development Act 51 
of 2008; and National Environmental Management: Biodiversity Act 10 of 2004. 
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The legislative framework regulating the patent system in South Africa is the Patents Act,52 
read alongside the implementing patent regulations. 53  There have since been various 
amendments to the Act and the implementing regulations. 54  With respect to patents on 
medicinal or pharmaceutical products the Medicines and Related Substances Control 
Amendment Act applies.55 This Act was later amended in 2008 and more recently in 2015. The 
South African Patents Act covers a wide range of patent related matters. 
South Africa has been a member of GATT since 13 June 1948 and a member of the 
WTO since 1 January 1995. 56  As a member of the WTO, South Africa signed TRIPS 
Agreement. Chapter 14 of the Constitution provides for the treatment of international law. 
Section 321(2) offers that “an international agreement binds the Republic only after it has been 
approved by resolution in both the National Assembly and the National Council of Provinces, 
unless it is an agreement referred to in subsection (3).”57 South Africa has since undertaken 
various domestic IPR framework reforms, to align its domestic IP framework to the TRIPS 
Agreement. 
South Africa’s IPR system is, for all intents and purposes, compliant with the TRIPS 
Agreement. It is observed though that this legal framework does not fully take advantage of all 
possible flexibilities provided for under the TRIPS Agreement and reinforced in the Doha 
Declaration. These reform areas have been covered by the 2018 national policy. 
To address a bourgeoning HIV epidemic, the country took measures to remedy this 
policy gap, which would allow it to leverage on the TRIPS flexibilities in order to secure access 
to ARVs, which were under patent and exorbitantly priced. To this end, the Parliament of South 
Africa passed the Medicines and Related Substances Control Amendment Act 90 of 1997.58 
This was the government’s attempt to increase access to essential medicines, which were out 
of reach due to patent monopolies and exorbitant pricing. Between the years 1999-2005, 
numerous initiatives were undertaken in the country to ensure access to affordable medicines. 
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The need to review the South African patent system has not gone unnoticed by the 
government. In June 2009, South Africa’s Department of Trade and Industry (DTI) initiated 
processes to commence debates focused on reforming the country’s IP architecture. The DTI 
announced plans to release a policy document for reform of South Africa’s IP legislation as 
early as 2009.59 
The DTI has since been engaged in negotiation processes to reform the IP landscape. 
This resulted with the tabling of a Draft National Policy on Intellectual Property of South 
Africa: A Policy Framework, in September 2013.60 The draft Policy detailed, in 17 chapters, 
various existing gaps within South Africa’s patent architecture. The purpose of the Policy was 
to argue for the Policy to talk to the other relevant national policies and international 
agreements that advance the aspirations of a developing national and to co-ordinate the national 
and international approaches on various IP matters. It recognised that “South Arica does not 
have an IP Policy and therefore, its approach to IP matters is fragments and not informed by 
national policies.”61 
The Draft Policy recognised the inherent policy incoherence experienced by the country 
to harness the flexibilities afforded by the TRIPS Agreement. It stated that South Africa is a 
developing country with the bare minimum of a technological, economic and social base. 
Further that policy makers need to consider available empirical evidence before extending IP 
rights, since the interests of the producer dominate in the evolution of IP policy, while the 
interests of consumers are ultimately compromised.62 
The DTI allowed for submissions from the public and interested parties on the Draft 
Policy. Three years after the draft National IP Policy, the DTI released an Intellectual Property 
Consultative Framework (as approved by Cabinet) on 6 July 2016. 63  The purpose of the 
Consultative Framework was ‘to put forward the perspective of the DTI in a consultative 
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instrument to facilitate what will be continuous engagement with governmental partners and 
society at large.’64 
The Framework observed that South Africa is robustly engaging with issues that 
concern the intersection between IP and public health. It cited the government’s stance in 
Pharmaceutical Manufacturers Association of South Africa v the President of the Republic of 
South Africa as a key factor leading to global dialogue around the potentially negative impact 
of IPRs on public health, culminating in the Doha Declaration on TRIPS and Public Health.65 
After three years of intense negotiation and consultative processes with national and 
international experts, academics and IPRs interest groups, the DTI launched the Intellectual 
Property Policy of the Republic of South Africa Phase I, on 31 May 2018.66 The new policy 
addresses numerous core issues such as patentability criteria, parallel importation, disclosure 
requirements, CLs, exceptions, and research. 
Articulation of compulsory licensing and abuse of patents under the South Africa’s patent 
regime 
South Africa has never issued a CL. From the analysis undertaken, threats of the 
issuance of CL have been documented, but in most of these cases, settlements have been 
reached out of court and mainly through rulings of the Competition Commission.67 In all the 
cases noted so far, threats of compulsory licensing have rather resulted in the issuance of 
voluntary licences. 
In the current Patents Act, CL is dealt with under sections 4 and 55-56 of the Patents Act. 
Section 56 of the Patent Act provides for “Compulsory licence in case of abuse of patent 
rights”. The grounds for these CLs are listed under subsections 56 (2) (a), (c) and (e) of the 
South Africa the Patents Act. These four grounds upon which an applicant for a compulsory 
licence can establish an abuse of patent rights include: 
• Failure to work the invention in South Africa within the prescribed time;68 
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• Insufficient supply to meet demand on reasonable terms;69 
• Refusal of the patent holder to grant a licence on reasonable terms;70 and 
• Excessive pricing in comparison to the price charged for the same item in other 
countries by the patent holder.71 
The breakdown of the process to apply for such licences are outlined under sections 56(1) –
(13) of the Patent Act. The procedures are set out under sections 8 and 19(1).72 While the Act 
provides for a CL mechanism, the system has been criticised for being onerous and difficult to 
enforce. This is primarily because applications for CL (even in the abuse of patents) are 
bureaucratic. As expanded above, these warrant lengthy and costly judicial processes prior to 
grant. This happens while there is no TRIPS obligation or requirements for South Africa to 
continue with such a burdensome procedure in granting a CL.73  
Article 1 of TRIPS states that members are “free to determine the appropriate method 
of implementing the provisions of this Agreement within their own legal system and 
practice”.74 One recommendation that has been put forth has been to amend the provision to 
allow for a range of “public health grounds” for issuance of licences. Chan Park et al are of the 
view that a remedy could be couched to allow for any application for a CL to be presented 
before the Patent’s Commissioner instead of a full judicial proceeding. This could simplify the 
current mechanism which is cumbersome and could take up to three or more years fully to 
litigate a matter, from the time the application is brought before the Commissioner, through 
litigation and including subsequent appeals.75 There is also no guidance in the law as to the 
time period within which prior negotiations must occur, nor on the royalty rates to be paid to 
patentees.76 
Compulsory licences jurisprudence in South Africa 
As mentioned previously, South Africa reformed some of its other laws and policies to 
ensure an environment in which medicines were accessed at affordable prices. During the same 
year as the incorporation of sections 55 and 56 of the Patents Act, the Medicines and Related 
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Substances Control Act (Act 101 1965) also underwent amendments. The most notable being 
the introduction of Section 15C, titled “Measures to ensure supply of more affordable 
medicines.” 
Section 15C reads:  
“The Minister may prescribe conditions for the supply of more affordable medicines in 
certain circumstances so as to protect the health of the public, and in particular may – 
(a) notwithstanding anything to the contrary contained in the Patents Act, 1978 (Act 
No. 57 of 1978), determine that the rights with regard to any medicine under a patent 
granted in the Republic shall not extend to acts in respect of such medicine which has 
been put onto the market by the owner of the medicine, or with his or her consent”77 
These amendments to the Medicines and Related Substances Control Act were met with 
opposition and this Section received similar treatment. The crux of the disapproval was that 
the insertion of section 15C into the Medicines and Related Substances Control Amendment 
Act would be tantamount to a violation of the TRIPS agreement. As a result, the country was 
faced with threats of economic sanctions from the United States as documented in the US 
Public Law 105-277 (105th Congress, 1999).78 In an effort to block this passage of this critical 
amendment into law, the Pharmaceutical Manufacturers’ Association (PMA) and 39 of its 
member instituted a legal challenge in February 1998.79 The three year court battle ended in 
2001 when the PMA withdrew its court challenge. Despite these oppositions and the on-going 
court case, the Medicines and Related Substances Control Amendment Act No. 90 of 1997 was 
signed into law on 12 December 1997. 
Notwithstanding the promulgation of this new section in the Act, the country continued 
to face challenges in leveraging on compulsory licensure to enable access to foreign produced 
pharmaceutical medicines. Rather than addressing the abuse of patent rights through section 
56 of the Patents Act, competition law seems to be the legislative piece employed to address 
exploitative abuses outside and within the pharmaceutical sphere. 80  Section 8 of the 
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Competition Act provides for abuse of dominance. Section 8(a) of the Competition Act of 
South Africa prohibits a dominant firm from charging an excessive price to the detriment of 
consumers.81 It empowers the Competition Commission of South Africa (CCSA) to investigate 
exploitative price abuses in any sector of the economy. 
When analysing South Africa’s experience in attempting to exploit this CL mechanism 
in case law related to pharmaceutical patents, South African competition law has been the point 
of departure to regulate and manage anti-competitive behaviour in securing fair pricing.82 On 
March 7, 2001, the Indian pharmaceutical manufacturer CIPLA formally requested the South 
African Department of Trade and Industry (DTI) to issue CL to patents on the following HIV 
drugs: Nevirapine, Lamivudine, Zidovudine, Stavudine, Didanosine, Efavirenz, Indinavir and 
Abacavir. The request was filed in terms of section 56(c) of the Patent Act. In its demand, 
CIPLA noted that “there are from 4 to 5 million HIV infected persons in South Africa, and less 
than 2 percent are receiving antiretroviral treatment.” 83 
The Competition Commission of South Africa offered a progressive decision in the 
infamous 2002 Hazel Tau case against GlaxoSmithKline (GSK) and Boehringer Ingelheim 
(GI). 84  The complaint was laid by individuals affected with HIV/AIDS, health care 
professionals, trade unions and several NGOs. The nature of the complaint was an allegation 
that GSK and BI violated section 8(a) of the Competition Act by charging excessive prices for 
their patented ARV medicines. The CCSA found that GSK and BI were in contravention of the 
sections 8(a), (b) and (c) of the Competition Act of 1998 by refusing to give competitors access 
to an essential facility or engaging in a general exclusionary act where the anti- competitive 
effect outweighed any efficiency gains.85 This case led to a settlement between the plaintiffs 
and GSK and Boehringer Ingelheim that included obligations to license generic manufacturers 
to supply the GSK and BI ARV drugs throughout sub-Saharan Africa. 
In 2016, the CCSA completed a study on the impact that the Hazel Tau settlement had 
on the provision of ARVs. The study, which was based on pricing data from 2000 to 2015 
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found that the prices of ARVs had decreased by more than 11% per annum, on average, and 
that an estimated cost saving of US$887m had been realised over the period, much of which 
accrued directly to the state.86 
The CCSA also continues to be the platform of ‘first instance’ where excessive pricing 
in innovative medicines. In their 2018 analysis on cancer drugs pricing, Bangalee and Suleman 
highlight the recent investigations by the CCSA into three global pharmaceutical companies, 
Roche Holding AG (Roche), Pfizer Inc. (Pfizer) and Aspen Pharmacare Holdings Ltd (Aspen) 
for suspected excessive pricing of cancer medicines in South Africa.87 These companies have 
been accused of engaging in excessive pricing, price discrimination and/or exclusionary 
conduct in the provision of breast cancer medicine in SA.88 It remains troublesome that the 
threat of competition legislation to address anti-competitive practices and abuse of patents does 
not act as a deterrent to multinational corporations engaging in excessive pricing and price 
dominance in the pharmaceutical industry. The South African Competition Act (as amended in 
2000) continues to be the point of departure.89 
Evolution of compulsory licencing measures in South Africa 
Efforts to simplify and expand the onerous judicial nature of the currently compulsory 
licensing mechanism through legislative amendment of the Patent Act have, in the past, been 
met with disapproval. This was evidenced in the 2002 proposal to the Standing Committee on 
Private Members' Legislative Proposals and Special Petitions to enable the exploitation of 
“compulsory licensing for non-commercial use of patented articles, as well as for compulsory 
licensing in the case of a national emergency”.90  
This proposal was rejected by the South African DTI, which tabled a submission on 19 June 
2002, putting forward arguments against this motion. 
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Growing momentum by actors calling for the review and reform of the current 
compulsory licensing mechanism was captured in the Draft National IP Policy in 2013. Chapter 
2 of the Draft National IP Policy recommended that, “Compulsory licensing should be 
introduced in South Africa in line with international treaties, such as the Doha Decision 6 of 
the WTO negotiations on Trade and Public Health”.91 
Three years after those submissions, the DTI launched the Intellectual Property 
Consultative Framework in 2016.92 As a policy discussion document, the Framework was the 
DTI’s first true attempt to analyse the inadequacies of the current compulsory licencing 
mechanism as afforded by the Patent Act. It provided great scope for interrogation of the 
weaknesses that have been chronicles over the last 15 years by IP experts, academics and 
various access interest groups. 
Noting that South Africa is yet to issue a CL, despite the Patents Act providing for this 
mechanism, the Framework refers to the conditions set out in the TRIPS Agreement for the use 
of CLs by member states.93 It appreciates that while voluntary licensing arrangements are 
crucial to efforts to provide access to affordable medicines, the promotion of sustainable 
supplies, are inadequate. 
The Framework calls for the review of the CL mechanism. Besides the hurdles 
contained in the practical implementation of the mechanism, it identified opportunities and the 
critical role that South Africa can play in offering CLs for export.94 In terms of compulsory 
licensing for export, the Framework appreciates calls by WTO members and IP experts in 
streamlining of the Paragraph 6 mechanism. 95  It notes that the government “will engage 
constructively within the WTO structures to find ways of streamlining the Paragraph 6 
mechanism”.96  
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The problem highlighted in the national IP Policy 2018 was highlighted in the IP 
Framework. Equally that, “the current South African Patent Act do not take full advantage of 
TRIPS flexibilities and that the judicial process provided by the Patents Act is in general, more 
cumbersome than required in TRIPS.” As a policy discussion document, the Framework is 
lauded as a bold attempt to critique the compulsory licencing mechanism and to find pathways 
for the government to start engaging in a reform process. 
The Intellectual Property Policy of the Republic of South Africa Phase I, was finally launched 
in May 2018 (national IP Policy) and has been welcomed as the first comprehensive national 
Intellectual Property Policy.97 The National Policy clearly articulates how the South African 
government envisages reviewing its current Patent Act to bring it in line with the TRIPS 
Agreement and the Doha Declaration. It identifies (amongst others) the current provisions for 
government use and compulsory licencing provisions being areas which require attention in 
the reform process. 
The national IP Policy of 2018 aligns itself to the Recommendations of the United 
Nation’s General Secretary’s High Level Panel (UNHLP) on Access to Medicines, by 
affirming that “almost fifteen years later, the UNHLP reiterated the importance of compulsory 
licensing and the sovereign right of states to make use of it, including ensuring the expedient 
use of compulsory licences or government use provisions.”98 The protracted negotiation and 
drafting processes that have been involved in systematic IPR reform over the last twelve years 
under the stewardship of the Department of Trade and Industry has culminated in the launch 
of a comprehensive National IP Policy, 2018.  
This Policy is aligned to the National Development Plan (NDP), calls for a greater 
emphasis on innovation, improved productivity, an intensive pursuit of a knowledge economy 
and the better exploitation of comparative and competitive advantages.99 It paves the way for 
a systematic overhaul of the patent system. For the purposes of this dissertation, it offers 
aspirational language for the review, revision and expansion of the currently and proposes 
installation of a more workable CL system. Appreciating the limitations of voluntary licences 
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and the need for sustainability of supply, this system is envisaged “to achieve affordability of 
essential goods, and restrain anti-competitive practices, as the needs arise.”100 The longer term 
vision as stated in the policy is that the government has renewed its efforts to facilitate the 
process of exporting IP goods, such as medicines, to the African continent. No procedures have 
been stated as to how the reforms will take place. The only thing expressed is that in order ‘to 
facilitate this, the government will engage in the development of guidelines, including legal 
process for government use.’101 
As has been discussed in this Chapter, South Africa has clear concerns about its public 
health challenges as was outlined in the first section of the Chapter. The prices of 
pharmaceutical medicines continue to be problem that the country has tried to address through 
various legal and policy measures, including the numerous reforms. The Chapter summarised 
the countries CL journey and the co-dependent relationship between the patent and competition 
laws. The co-application of these laws has in the past provided reprieve in cases of excessive 
pricing of medicines. This has recently been observed in the case of non-communicable 
diseases such as the cancer. 
The country now wishes to reform its IPR regime, to support its neo-liberal growth 
imperatives. In doing so, South Africa has published a national IP Policy (2018), which outlines 
commitments to revising the current CL mechanisms, accepting criticisms that have been 
levelled against the mechanism. What is clear is that the policy wishes to engage in a review 
process that will install a CL system which plays that the role of a cost-containment 
mechanism. Where the role of competition law is concerned, the Policy appreciates the long 
history and intersections between competition rules in patent law in cases involving IP and 
public interest. The policy reinforces and maintains the co-existing relationship between 
competition and patent law. 
The following chapters follow Russia and China, two counterparts that have renovated 
their CL mechanisms to translate into cost containment mechanisms in the abuse of patents, 
safeguard access to essential medicines and to enhance their own local pharmaceutical 
industries. It is hoped that South Africa can learn from these models of approach. 
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Chapter 3: Reviewing the evolution of compulsory licensure as a cost containment 
mechanism for access of medicines in the Russian Federation 
Following the similar trajectory of the previous chapter, this chapter is meant to provide 
a broad overview of the IPR legal landscape in the Russian Federation (herein referred to as 
‘Russia’). This counterpart boasts a complex socio-political history and is often noted that one 
of the world’s largest transitional economies. This resulted in the country having to overhaul 
its entire IPRs landscape in order to integrate into the international trade system. Having 
adopted a fragmented public health system from its predecessor the Soviet Socialist Republics 
(Soviet Union), the reforms which followed required versatility in the way this counterpart 
responded to the international trade rules. This was in order to address some of its public health 
concerns to accessing affordable medicines. 
For the purposes of this minor dissertation, the broad focus will be on the IPR legal reforms 
that were initiated to transition its domestic laws and complementary policies. A key area of 
concern is how Russia navigated abuse of patent rights, as it does not expressly have a provision 
within it the Civil Code. This has been a critical mechanism used in addressing some of IPR 
barriers posed to the affordability of medicines, over and above relying on the protectionist 
mandate offered by competition law. 
The outline of the Chapter is as follows: (i) A short overview of the Russian Federation’s public 
health system architecture pre- and post-Soviet Union collapse and the policy reforms that 
followed. A background of the Russian economic development and integration into the global 
trade market after the dissolution of the Soviet Union. (ii) The developments of Russian’s IPR 
architecture post-Soviet Union collapse. The offering will not chronicle the early historical 
developments which have shaped this country’s IP landscape. It appraises the critical events 
which have influenced the modernisation of the IPR regime. (iii) The paper then undertakes a 
quick review into the interplay between IPR and competition Law to see whether Russia has 
considered competition law as a primary point of defence in circumventing abuse of patents 
rights. This includes its accession into the WTO and its obligations under the TRIPS 
Agreement. (iii) This Chapter will then explore the evolution of compulsory licensing measures 
in Russia’s legal landscape in order to see how its approaches have differed or have similarities 
to those of South Africa. 
An overview of the Russian Federation’s public health system architecture pre and post-
Soviet collapse and the key policy reforms 
As a republic forming part of the Soviet Union, Russia had to comply with the dictates of the 
Union’s public health care laws, policies and regulations. The Soviet state established this 
system during the 1930s and 1940s as part of rapid modernisation and industrialisation.102 This 
public health system enjoyed decades of growth and significant improvement in the period 
preceding the 1980s. In a Working Paper on the constraints in achieving Universal Health Care, 
Professor Cook notes that by the 1980s the accumulating problems of bureaucratic rigidity, low 
levels of medical technology, underfinancing and failed reform efforts were contributing to the 
deterioration of health conditions among Russia’s population.103 
The period post-Soviet Union collapse saw Russia engage in attempts to modernise its public 
health system. In a 1990 analysis of the changes in life expectancy in Russia, Shkolnikov et al 
found that Russia is one of the few developing countries where life expectancy had reduced 
during that period. The collapse of the Soviet Union in 1991 led to the precipitous decline in 
health status of the Russian population. According to the WHO Regional Office for Europe, a 
combination of a dramatic fall in the birth rate and increasing mortality meant that since the 
mid-1980s, Russia’s population has shown declining growth rates, which became negative in 
1992.104  
Following the 1993 Constitution, the country comprises 89 administrative units or regions. The 
regions are extremely diverse in terms of their economic resources, geographical size and 
population, climate and dependency on the federal government.105 This historical overview of 
Russia’s public healthcare architecture provides contextual understanding of the uphill battle 
the country faced in addressing its communicable and non-communicable health challenges 
while reforming its health care system. 
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In an effort to decentralised provision of healthcare services, Russia introduced a health 
insurance legislation in 1993.106 The goal was to infuse new nonbudgetary revenues into the 
system and introduce efficiency by separating financing from provision.107 The system which 
was implementing from 1993, was owned by local governments with revenue to fund what was 
terms the Territorial Health Insurance Funds (THIFs) in the 89 regions accessed through 
payroll tax on enterprises (3.6%).108 However, the limited participation of insurance companies 
and with limited oversight by the Ministry of Health, the implementation of the legislation 
lacked guidance, due to a lack of appropriate administrative and financial mechanisms. This 
led to the Ministry of Health assuming full control of the THIFs and in developing appropriate 
social policies to ensure a more harmonised approach. 
Access to pharmaceutical medicines and commodities in the Russian Federation 
Like other developing countries Russia faced and continues to experience challenges in 
ensuring sustained access to health services, including accessing of health commodities and 
essential medicines. The price of HIV treatment remains a growing concern in the Russian 
Federation. Taking HIV as a disease case study, official statistics provide that 1 007 369 
Russians were living with HIV by the end of 2018. The treatment coverage in the Russian 
Federation was 42.4% of the number of people living with the diagnosis of HIV infection, and 
58.9% of those who were under medical check-up in dispensaries.109 
The mostly commonly used HIV treatments on Russia’s Essential Medicines List were mainly 
procured from external manufacturers and three were from localised Russian manufacturers. 
The manufacturers of ARV drugs are divided into three segments: large international 
pharmaceutical companies (AbbVie, BMS, Gilead, Janssen, MSD, Roche, ViiV), Indian 
companies specialising in production of generic drugs (Aurobindo, Hetero, Ranbaxy), as well 
as Russian firms (including Biocad, Drugs Formulation, Pharmasyntez). 
Seventeen ARV drugs within Russia’s Essential Medicines List did not have analogues (or 
drugs with similar chemical compounds) in the local market. This is mainly due to patent 
protection. In the area of ARV procurement, 68.7% of the national budget was spent on the 
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procurement of five drugs (lopinavir/ritonavire, raltegravir, tenofovir/emtricitabine/rilpivirine, 
etavirine, atazanavir). 60% of this was spent on four drug products under patent protection 
(lopinavir/ritonavir, raltegravir, tenofovir/emtricitabine/efavirenz, etravirine). 110  The same 
report notes that the cost of second-line regimens in 2018 ranged from US$966 to $1 833 
(between ZAR14 250 – ZAR27 000) per patient per year. Being reliant on external 
manufacturers substantially increased the price of drugs.  
In evaluating the efficiency and return on investment of this programme between 2005 
and 2006, Ramil Khabriev et al observed that the most significant achievement of the DLO 
programme was that it has enabled free access to essential medicines for the most vulnerable 
and under-provided segment of the Russian population. 111  While this system recorded 
insurmountable success, its sustainability strategy remained weak. The challenges in sustaining 
the programme were documented by the Russian Ministry of Health Care and Social 
Development and the Federal Services who were the main custodians of the programme. While 
the DLO programme has undoubtedly had a significant positive impact on improving access to 
essential medicines, it has continued to operate within a fixed budget determined by the federal 
government. Further improvements were noted during this period. The government of Russia 
also instituted scaled up public health reforms with incremental budgetary increases. This was 
complemented by the President’s announcement of obligatory annual increases (beyond 
inflation) of medical insurance tax, to be paid by companies for compulsory medical insurance. 
In order to strengthen health policy, President Vladimir Putin launched a new three-
phased public healthcare stimulus plan entitled, the “Health 2020” Agenda in 2016. As part of 
its implementation strategy, the “Pharma 2020” plan was approved. This new programme 
aspires to produce virtually all essential medicines domestically by the year 2020. This new 
strategy has a strategic aspiration to produce innovative medicines and in order to achieve this 
Russia was forced to strengthen IP protection and enforcement. Through this plan, the 
government of Russia aimed to substitute 50% of all generic drugs with domestic alternatives 
by 2017 and domestically manufacture 50% of all innovative drugs by 2020.112 
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The evolution of Russia’s patent legislation and examining the impact of the TRIPS 
Agreement within its Patent/ IP legal and policy environment 
The post-Soviet scenario also saw the evolution of Russian Federation’s intellectual 
property rights regime. Butler observes that with the demise of the USSR, the protection of 
industrial property in Russia was in a desperate position. Further, that the 1991 USSR Law on 
Inventions was inconsistent with several Russian Federation laws, including those on taxation, 
enterprise, and investments.113 
Two critical periods are noted in the development of Russia’s IPR. Firstly, the first ever 
legal protection of IP in Russia has its origin in the “Manifesto on privileges for inventions and 
discoveries in the arts and sciences” of June 17, 1812. According to Zegelman and others, this 
Manifesto is considered to be the earliest Russian law protecting IPRs.114 Secondly, most 
historical studies looking at IPR reform in post-Soviet Russia start with the classic or late Soviet 
period (1960–1989) as a point of departure.115 According to Esprit Eugster, the development 
of IP and the legal regulation thereof were modelled on Soviet ideology, which dominated the 
republics during almost the whole twentieth century.116 
Attempts to reform the Soviet Union’s IP law culminated in 1991 when the circulation 
the Laws on Inventive Activity were adopted by the Soviet Parliament on May 31, 1991. This 
legislative piece was designed to overhaul the older system of protecting IPRs.117 Although 
these were lauded as being improvements, many critics observe that they remained largely an 
extension of Soviet initiatives, and that these amendments did not result in effectual legal 
reforms. According to Eugster, these reforms ended up being largely ineffective for deterring 
piracy because they were unclear, overly lax, and did not provide deterrent penalties.118 
The Federation’s legal system is a civil code system, which provides for judicial review of 
statutory law. The underlying structure of the Russian legal system possesses both civil and 
criminal components. Russian legal doctrine defines the law of IP as a sub-branch of the civil 
law system.119 This is supported by Article 2 of the Russian Civil Code according to which 
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exclusive rights to the results of intellectual activity (IP) are regulated by the civil legislation. 
The IPR laws are divided according to Russian legal doctrine into three institutions: (i) author’s 
right and neighbouring rights; (ii) industrial property; and (iii) non-conventional IP objects. 
The industrial property legislation is a complex institute consisting of several separate 
formations: (i) patents; (ii) means of individualisation; and (iii) unfair competition.120 
Until the promulgation of Part four of the Civil Code, the 1992 Patent Law remained 
the main source of patent legislation in Russia. The IP reforms that started in Russia in 2006 
were meant to replace the IPR laws of the transitional post-Soviet era with an IP legislative 
regime. The Russian Civil Code was incrementally amended in 1995 and in 2004, to further 
align Russian domestic law with the TRIPS Agreement and other bilateral obligations.121 
The Russian Parliament (the Duma State) undertook IP reform processes in 2006, which 
repealed the former IP laws. This led to the adoption of new IPR legislation, under part four of 
the Russian Civil Code. This Code came into force on 1 January 2008.122  
The most notable reform was the adoption of Part IV of the Civil Code (Part IV), which 
was signed on December 19, 2006 and came into force on January 1, 2008. Prior to the adoption 
of part four, the Civil Code was not a direct source of the IP law. However, its norms were 
applicable to the regulation of IP. In accordance to these legislative amendments, the IP regime 
now consisted of two successive levels. The first level is the Civil Code. This law provides for 
general regulation of civil legal relationships applicable also to IPR articulation. Specialised 
laws for other IP areas make up the second level. Professor Boris Mamlyk offers that the 
express goal of these two levels was to harmonise Russia’s entire IP regime and not merely 
individual normative acts, but the entire regulatory and enforcement system—with the 
standards set forth in multilateral conventions, namely TRIPS, but also other conventions.123 
Mamlyk documents three critical periods of radical IP transformation that the Russia’s 
IP system underwent after the collapse of the Soviet Union.124 The first was known as the 
“indigenous change” period. It took place between 1992 to 1994 and culminated in law reform 
proposals originating from working groups established in the dying days of the USSR.125 The 
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second transition period took place between 1995 to 2006, and this is referred to as the period 
of “legal transplantation and vertical harmonization.” 126  This period focused on the 
relationships between Russia and international trade bodies such as the WTO as the country 
was translating and aligning its laws in accordance to international law standards. The third 
period corresponds to the adoption of Part IV of the Russian Civil Code on November 24, 2006 
(effective January 1, 2008), which supersedes all previous legislation relating to IP and to bring 
Russian law into compliance with international obligations.127 
Most of the criticisms levelled against this new body of Russia’s IP laws was the 
country’s inability to enforce these legislative changes. Proponents are of the view that Russia’s 
ability to engage in the international marketplace could be jeopardised by its lax enforcement 
of IPR and legislation, which falls short of international standards and treaties.128 Eugster cites 
Russia’s 2006 unsuccessful attempts to accede to the WTO in 2006 and the low investor 
confidence in the country, as examples of the incoherence of her IP laws.129 
Articulation and implementation of Compulsory Licensing under the Russian Federation 
Civil Code 
As per the Russian Civil Code, a CL for a patent can be granted in two instances. Firstly, 
if an invention is not used or is being insufficiently used. Secondly, if there is a second 
dependent patent which one cannot use without infringing the first patent. As will be further 
explored in this section, these two provisions have long been in the Russian legislation. 
However, until recently there had not been any real cases where a CL was granted in Russia.130 
The Russian Federation became the 156th WTO member on 22 August 2012. 131 
Russia’s accession into the WTO meant that further amendments were required to its Civil 
Code, in order to align its IPR regime to international standards. Therefore, Articles 1360 and 
1362 of the Russian Civil Code, were duly amended.132 Article 1360 allows for the use of an 
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  Articles 1362(1)-(3) provide for Compulsory License to an Invention, Utility Model or 
Industry Design.133 The current Russian legislative framework allows a CL to be issued only 
by the court in case a patent holder does not use an invention, and this leads to a lack of relevant 
products or services in the Russian market.134 Russia does not provide for CL in the case of 
abuse of patents. 
Since 2013, the Russian Ministry of Health, Federal Anti-Monopoly Service (FAS) and 
key opinion leaders in Russia have debated expansion of the use of CL as a pharmaceutical 
cost containment tool.135 In February 2014, the FAS proposed authorising CLs as a manner of 
mitigating costs of drugs in certain areas of public health.136 Since then there have been other 
proposals for the furtherance of more flexible CL measures as this is seen as an essential tool 
to advance access to medicines in areas of high need. 
In April 2016, the FAS designed a scheme to increase the scope of CL in Russia. The 
FAS argued that Russia’s dependence on manufacturers of patented drugs with no Russian 
analogues is a state security threat. It argued that there have been examples of cases where a 
sole manufacturer of a drug has refused to supply its product in Russia.137 In 2017, the FAS 
proposed an amendment to Article 1360 (the government use provision) of the Civil Code, to 
allow for expansion of the ground for compulsory licensing, to include the protection of “public 
health and safety” and empower the FAS to issue a CL without court approval, if conditions 
are met.138 According to McDonald et al, the proposal to amend Article 1362 (the compulsory 
licensing provision) to enable the Russian government and others to file a suit for compulsory 
licensing upon a finding that the patent holder has committed an antitrust violation, which it 
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currently does not provide for - was withdrawn by the FAS late in 2017, and replaced by 
another proposal.139 
A second proposal was tabled by the FAS in April 2017. It forwarded amendments to the 
Federal Law on Circulation of Medicines to authorise the Government to establish a procedure 
for government registration of medicines subject to CL. The proposal which offered safeguards 
against “monopolistic activities and unfair competition” was withdrawn by the FAS after an 
assessment of the regulatory impact was undertaken by the Ministry of Economic 
Development.140 
The FAS continues to experiment with alternative avenues to push for the installation 
of CL as a cost-containment measure and as a deterrent in cases of abuse of patents. The FAS 
strategically leveraged the launch of the National Plan for the Development of Competition for 
the years 2018-2020 at the end of 2017, as another entry point. This objective of this plan is to 
“encourage economic development and improve the well-being of the population of Russia”.141 
It allows the Russian Government to draft laws that advance the utilisation of patented 
inventions through its decision, if such measures are required for defence and security, 
including protection of human life and health.142 
At the sixth BRICS Competition Conference held in Moscow Russia in September 
2019, the Deputy Head of the Legal Department of the Antimonopoly Service announced that 
a the FAS had submitted a Bill to the State Duma on the introduction of a new version of Article 
1360 of the Civil Code of the Russian Federation on compulsory licensing. The proposed 
changes in the law are supposed to allow the government the right to grant patents, “in case of 
emergency, related to ensuring the defence and security of the state, protecting the life and 
health of citizens”143 
The above proposals for relaxation of compulsory licensing measures also form part of the 
Duma State’s efforts to implement the “Roadmap for Development of Competition in 
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Healthcare” that was released on 12 January 2018.144 The Roadmap is said to be a tool that will 
limit the scope of patent protection for pharmaceutical products. It identifies three areas of 
focus in the arena of IPRs protections: 
i. Clarification of conditions on patentability of new properties and application of 
previously known pharmaceutical substances; 
ii. Establishment of periods for the examination of patent applications by Russian Patent 
and Trade Office (Rospatent); 
iii. Development of procedures for implementation of compulsory licensing provisions 
proposed by FAS by way of amendments to Article 1360 of the Russian Civil Code. 
As at drafting of this dissertation, the Bill was yet to be released for public consumption. 
Case law pertaining to the issuance of CL 
There have been recent advancements in cases on issuance of compulsory licensure in 
the Russian Federation. The first attempt for grant of a compulsory license for abuse of patent 
right and anti-competitive behaviour was made by TEVA in a patent dispute with 
DEBIOPHARM S.A. in 2011.145 However, the lawsuit was withdrawn by TEVA. 
Other matters have been brought before the FAS or instituted this body. Yet, the FAS faces 
struggles with the immunity that the competition rules grant multinational companies. These 
companies justify their anticompetitive behaviours by citing antitrust “immunities” afforded 
by the “On Protection of Competition” under the Federal Law.146 These antitrust “immunities” 
for intellectual property are justifiable as they are in compliance with Part 1 of Article 13.  The 
Article states as follows: “The actions (omission to act) of the economic units provided for by 
Part 1 of Article 10 of this Federal Law… may be declared permissible, if such actions 
(omission to act), do not make it possible for some persons to remove competition in the 
appropriate commodity market, do not impose with respect to their participants or third persons 
the restrictions not complying with the attainment of the aims of such actions (omission to act), 
as well as if they result or may result in the following: 
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1) improvement of production and of commodities' sales, or stimulation of technological 
or economic progress, or enhancement of the competitive ability of Russian- made 
commodities in the world commodity market; 
2) purchasers' gaining advantages (benefits) comparable to the advantages (benefits) 
gained by economic units as a result of actions (omission to act), agreements, concerted 
actions and transactions”147 
The legal protections that multinational companies can invoke, challenges both the efforts by 
the FAS and raises questions around the protectionist mandate of the country’s competition 
law. 
There have recently been cases dealing with dependent patents and inventions not used or 
insufficiently used. In March 2017, Celgene, a US biotech pharmaceutical company, filed a 
patent infringement lawsuit against Nativa, a Russian drug manufacture. This was to ban the 
production and sales of Lenalidomide, an active pharmaceutical ingredient under the trade 
name, Revlimid. The matter was heard by the Moscow Arbitration Court.148 
Nativa, which is embroiled in lawsuits by six other major pharmaceutical companies, 
filed a counter claim requesting the court to permit a compulsory licensing of this drug in the 
Russian market. This is subject to Nativa’s dependent patent RU 2 616 976, which is a new 
crystal form of Lenalidomide (polymorphic form B). According to Russian generics 
companies, the government procured Lenalidomide from Celgene for an amount of about 9 
billion rubles per year. In the Federation, the drug is patented by Celgene under Patent RU 
2595250. The patent protects corresponding compounds, as well as any product that comprises 
this active ingredient. By force of a patent term extension (PTE / SPC), this patent has been 
extended to 25 July 2022.149 
On 15 June 2018, the Court granted a CL to Nativa to use the patent of US biotech major 
Celgene for the production of its Revlimid (lenalidomide) within Russia.150 The court came to 
the conclusion that the conditions for the grant of a CL were fulfilled, in that “the dependent 
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patent must represent an important technical achievement and shall provide significant 
economic advantages over the earlier dominant patent.”151 The amount of royalties which need 
to be paid by Nativa to Celgene has been fixed to 30% of the profit that will be achieved by the 
generic product, with global sales of this drug amounting to US$12 billion in 2016. This licence 
represents the first CL in the Russian Federation in the area of the pharmaceutical industry. 
The gravity of the above decision cannot be understated where dependent patents are 
concerned. This decision sets a progressive precedent where issuance of CLs for dependent 
patents is concerned. In his analysis, Maxim Sobolev, a patent and trademark attorney observes 
that the decisions might prove to be an important technical achievement for the country and a 
significant social protector.152 This is because the court did not only focus on the aspect of 
foreign products. In the Celgene case, the court explained that a CL is granted on the grounds 
of economic development, country security or when it is socially significant. 
Conclusion 
As has been noted in this Chapter, although Russia continues to review and reform their 
IPR regime, the limitations lies in the country’s inability to enforce these. The tenacity of the 
FAS is noted in their efforts to advocate for policy reforms and strengthened parameters for 
CL to protect public health interests. These proposals have been supported by various 
Ministries, civil society and generic manufacturers. It is also apparent that there is 
overwhelming opposition to these proposals even from Rospatent and the Russian Ministry of 
Economic Development. The opposition is largely driven by assertions that such measures will 
not necessarily reduce the prices of these commodities and that the current legislative 
framework is sufficient. 
There are major concerns that the proposed statutory amendments will negatively affect 
foreign direct investment, yet these assertions are not supported by convincing evidence. The 
recent approach taken by the Moscow Arbitration Court offers instructive food for thought 
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where the issuance of “dependent patents” is concerned. Though these cases are not related to 
abuse of patents directly nor do they deal with anticompetitive practices. 
As seen from this Chapter, Russia’s compulsory licensure award system is similar to that of 
South Africa’s in that this is a judicial procedure and most of the cases have been on the basis 
of dependent patents.153 From this Chapter, it is apparent that the proposals by the FAS have 
taken a more aggressive stance in its efforts to refine and installing a workable compulsory 
licensing mechanism especially in respect of abuse of patents and in safeguarding public health. 
This is a sneak preview of the uphill battle the DTI and other proponents will have to face in 
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Chapter 4: Reviewing the evolution of compulsory licensure as a cost-containment 
mechanism for access of medicines in People’s Republic of China (PRC) 
The purpose of this Chapter is to evaluate IPR policy landscape in the People’s 
Republic of China (PRC). It prides an overview of the advancements made in the public health 
systems and it has evolved over time. More specifically, the Chapter focuses on the IP and 
patent implementation modalities this counterpart has opted for over before and after its 
assertion to the WTO. Further, how it has approached compulsory licensure under the national 
IP strategy. China’s efforts to advance a progressive IPR regime has been a vehicle to 
strategically advance the national growth agenda. Its policy approaches have been deliberate 
and intuitive to its contextual needs, to ensure that it installs CL measures that complement the 
country’s broader development roadmap. 
The outline of the Chapter is as follows the similar structure as the previous two 
Chapters. It concludes by outlining some of the challenges presented by the current regulation 
of CLs. This exploration is done to gauge the effects of China installing separate CL 
Implementing Measures and the results of this exercise. 
 A snapshot of the PRC’s public health reform processes since 1949 
Since its birth as the People’s Republic of China (PRC) in 1949, the country has 
undertaken a series of remarkable health system experiments that are instructive at many 
levels.154  It is observed that the revolution of China’s public health agenda was largely been 
shaped by the major health care reforms that took place in the late 1970s.155 Between 1949 and 
the late 1970s, the Chinese health care system was organised on a county-township-village, 
three-tiered system. This meant that legally recognised “foot doctors” (also referred to ‘lay 
community counsellors’) delivered health care services at various levels. Health care was also 
almost offered free of charge as all health care facilities and related services were state-owned. 
Therefore, there was no need for health insurance.156 
The health care policies that were introduced in 1984 ushered in an era of 
comprehensive reforms, heralding changes such as the abolition of free access to health care 
and implementation of free-market reforms.157 This resulted in the privatisation of health care. 
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Foreign enterprises were introduced to catalyse rapid economic growth. In her thesis, Amy 
Phou offers that these reforms led to a reduction in the central government’s investment 
towards health care and public services, eventually leading to the introduction of local taxation 
by provincial authorities, as a measure to cover the shortfall.158 
Blumenthal and Hsiao observe that China has faced insurmountable challenges over the 
last six decades in adapting its health care system to this free market economy. This resulted in 
the privatisation of hospitals with only 7% of those living in rural regions having health 
insurance by 1999.159 The introduction of the health care insurance by 2003 was an intervention 
to quell the mass discontent of Chinese citizenry. By 2008, the efforts to introduce a minimum 
health care insurance as well as scaling down of a private-towards-public delivery system were 
interventions to sustain social stability. It is also noted that by 2012, the government-subsidized 
insurance system was providing close to 95% of the population with modest but comprehensive 
health coverage. To fund this healthcare coverage, the government offered private investors 
20% ownership in Chinese hospitals.160 
This did not remedy the inequity in healthcare service delivery between rural and urban 
areas of the country. The system continued to suffer from the lack of a high-quality, trusted, 
professionalised physician workforce and with the eradication of the “foot doctors” – the gap 
was felt. In the last decade, the country has moved away from this free market system of health 
care and has started reintroducing the provision of affordable basic health care for all Chinese 
people by 2020. 
Sustaining access to quality affordable medicines in the PRC 
It is observed that while traditional Chinese medicines remain central to this country’s 
health care system, modern medicines were also introduced as early as the nineteenth century. 
The merger of urban and rural health sectors in the late 1970s influenced access to 
pharmaceutical commodities. The high pharmaceutical expenditure costs became a major 
obstacle to the effective delivery of health care in the country. “In 2010 alone, Chinese national 
healthcare expenditures were USD 289.6 billion, with out-of-pocket health expenditure of 
nearly USD 102.8 billion.”161 According to the Chinese Ministry of Health, pharmaceuticals 
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account for about half of total health spending in China, representing 43.4 percent of spending 
per in-patient episode and 52.2 percent of spending per outpatient visit.162 
By the late 2000s there was minimal traction in the proliferation of essential 
pharmaceutical medicines due to weak implementation resulting in further health system 
reforms. With an escalating non-communicable disease burden, the country proposed 
comprehensive health-sector reforms in 2009.163  
Central to this systematic overhaul of the health care sector was the installation of a 
national essential medicines policy which would ensure access to safety, quality and affordable 
medicines for its citizenry.164  This represented the Chinese government’s plan to achieve 
universal access by 2020 through the implementation of the Healthy China 2030: A Vision for 
Health Care (HC 2030) blue print. According to Hogerzeil and Jing, the aim of this Programme 
was two-tiered; it focused on medical and health care system reforms. They note that one of 
the key pillars of the reform process was the establishment and implementation of a national 
essential medicines policy to ensure the safety, quality, supply and affordability of 
medicines.165 
China’s ability to sustainably reduce expenditure of pharmaceutical products thereby 
increasing universal public access to affordable essential pharmaceutical products would be the 
true measure of success of its healthcare reforms and the HC 2030 blueprint. 
The impact of the TRIPS Agreement on the evolution of the PRC’s intellectual property 
and patent landscape 
A historical overview of the IP and Patent law system highlights that during its 
thousand-year history the Chinese Empire had never had a structured and uniform system 
devoted to Intellectual Property protection.166 The Chinese intellectual property system goes 
back to the twentieth century, starting with the Copyright Act of 1910 and the Patent Act of 
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1912.167 The notion of substantive intellectual property protections did not emerge until the 
early twentieth century. 
China’s IP legal and policy landscape has evolved over the last 35 years. In detailing 
this journey Professor’s Peter Yu’s offers that China’s economic evolution which morphed 
from a purely ‘socialist market economy to a more liberal trade portfolio’, benefitted greatly 
from its membership to the WTO.168 He opines that there was a certain level of fluidity with 
which this member state managed to harness the peculiar aspects of its Maoist strategy while 
maintaining a self-sufficient economy at both a national and global level.169 
China’s accession into the WTO in 2001 is significant for the country’s economic 
advancement. On December 11, 2001, the country formally became the 143rd member of the 
international trading body. Some experts are of the view that ‘the international trading system 
can ill afford to have a player as major as China not playing by the rules of the game.’170 While 
others opine that the WTO was only a partial worldwide trade organization before China’s 
accession.171 As complex and lengthy a process as this was; joining the WTO was seen as an 
opportunity for the country to ensure that its trade liberalisation reforms, included opening up 
more export-oriented opportunities was realised through implementing a unilateral trade 
liberalisation process.  
As a WTO member China also had an obligation to comply with the provisions of the 
TRIPS Agreement. Yu notes that China’s approach in complying with the TRIPS Agreement 
has been an incremental one.172 He holds the view that while the country has benefited from 
TRIPS-based intellectual property system. China ‘would not have reached its current position 
had it implemented the TRIPS Agreement to the fullest extent’.173 
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China’s IPR statutory landscape 
To facilitate the development of a market-oriented economy, China has created a 
systematic legal framework to protect IPR. The first Patent Law was passed by the Standing 
Committee of the People’s Congress and came into force on April 1, 1985, three years after 
China joined the World Intellectual Property Organisation (WIPO). It also adopted the 
Trademark Law, the Patent Law and the Copyright Law in 1982, 1984 and 1990, 
respectively.174 At the same time, China had acceded to the Paris Convention for the Protection 
of Industrial property.175  
As a result, the country’s patent law reflected numerous principles set in the Paris 
Convention. For example, the articulation of a patent right provided that, “Patentees have the 
right to prevent others from making, using or selling the patented products, or using the 
patented processes for production or business purposes.” It is noted that the law did not provide 
for patent protection of pharmaceutical products. 
During the period from 1982 to 1993, drugs were primarily protected by administrative 
measures.176 This was regulated through the Patent Administrative Bureau, a statutory body 
formalised under the Patent Act. These administrative measures were necessary because at the 
time of the negotiation of this first Patent Act, the Chinese Court system had just been re-
established. Given the limited human resources and the heavy civil and criminal case burdens, 
the Chinese government did not have the luxury to entertain patent related matters. Therefore, 
the Patent Administrative Bureau was created as a statutory government agency to resolve 
patent-related disputes.177  
Patent protection of pharmaceutical products was later provided for under the amended 
Patent Law in 1993. Since then, China has adopted the Copyright Law in 1990 and the Anti-
Unfair Competition Law in 1993. The revised Chinese Patent Law came into effect on January 
1, 1993. This was the known as the “Amendment of the Patent Law 1993”. From 1993 onwards, 
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China started issuing patent protection law for pharmaceuticals. 178  Patent protection for 
pharmaceutical products remains for twenty years. 
In providing an overview of the negotiations leading up to this legal amendment, Bonn 
Lin et al, provide insight into the Sino-American trade negotiations which influenced some of 
the amendments, leading to the two parties signing of a Memorandum of Understanding 
(MOU) in Washington DC on January 17, 1992.179 This MOU required China to amend its 
Patent Law. The core of the amendments included protection of chemicals and pharmaceutical 
products to extend the patent term of regular inventions from fifteen to twenty years, and most 
significantly to place strict conditions for the granting of CLs. It also provided for an expanded 
definition of a patent right to cover products directly obtained by patented processes and 
importation of patented products and products obtained directly by patented processes. CLs 
could be granted under strict conditions.180 
The accession of China to the WTO further led to legal reforms of its IP laws. China’s 
Patent Law was amended in August 2000. This was followed by complementary amendments 
to its Copyright and Trademark laws in 2001. The primary objective being to ensure that the 
Law was aligned to the requirements of the TRIPS Agreement. The revised Patent Law came 
into force on 1 July 2001. Article 3 provided for the de-centralisation of the Patent 
Administrative Bureaus which were set up at the provincial level. The revised law also 
provided for “Priority, Pre and Post Grant Examination” under article 29.181 
By 2005, the process to revise China’s Patent Law commenced. This resulted in an amended 
Patent Act in 2008. The new amendments incorporated, including provisions pertaining to 
procedures for the grant of patents and the ownership and management of patent rights. 
According to Ming Q. Lu et al, the amendment to Patent Law of 2008 was significant in terms 
of intellectual property protection as it adopted the international standards of novelty 
examination to conduct drug patent reviews and approvals. It incorporated new articles 
allowing for parallel importation, compulsory licensing, and Bolar exemption for drug clinical 
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trials and dossier applications. The law offered strengthened enforcement measures for drug 
patent protection by increasing administrative penalties for violations. 
On the 5th of June 2008, the State Council issued the “National Intellectual Property 
Strategy Outline” (NIP) which had the ultimate goal of establishing China into a country with 
a comparatively higher level of competency in terms of the creation, utilization, protection and 
administration of IP rights by 2020.182 The NIP proposed a set of key systematic changes in 
order to actively respond to international challenges and optimise China’s Intellectual Property 
(IP) system. Six years into the implementation of the NIP, the State Council launched the 
Action Plan for the Further Implementation of the National Intellectual Property Strategy for 
the period 2014-2020 (hereafter “the Action Plan”) in December 2014.183 In December 2015, 
the State Intellectual Property Office (SIPO) was renamed China National Intellectual Property 
Administration (CNIPA). On 28 August 2018, CNIPA published its final draft of the proposed 
revisions to the Chinese Patent Law. At the time of drafting this Chapter, the document was 
still in draft form. 
China intellectual property rights system has seen several reforms in the last decade. 
The country remains focused in its ambition to ensure robust protections for its pharmaceutical 
industry, extending to patent and trademarks protection. “Scholars note that many of the 
problems existing in the Chinese Intellectual property system are typical features of the 
transition from a centrally planned economy to a market economy.”184 Peter Yu, who is a strong 
proponent of the developmental approach to intellectual property protection offers that China 
is a paradigmatic example through which one can develop a better and deeper understanding 
of intellectual property law and policy, as it provides a more nuanced picture of the intellectual 
property development.185 
Implementation approaches of CL under the PRC’s patent regime 
China joined the WTO a month after the 2001 Doha Declaration was adopted. As the 
harnessing of a market-oriented economy was one of this member state’s primary goals, the 
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country created a systematic legal framework to facilitate the protection of IPR. The legal rules 
regulating compulsory licensing of IPR gradually evolved to include the protection of 
pharmaceutical products. 
Compulsory licensing in the PRC’s Patent Law of 1984 
The People’s Republic of China installed its first Patent Law in 1984.186 Under this Patent 
Law, the compulsory licensing rules were largely borrowed from the Paris Convention and was 
galvanised by the country’s eagerness to join the Paris Convention on the Protection of 
Industrial Property.187  Under the Patent Law, Compulsory Licensure was regulated under 
Chapter VI of the Patent Law, Compulsory License for Exploitation of a Patent.188 Article 48 
of Chapter VI provides “for certain circumstances under which the patent administration 
department under the State Council, SIPO; may upon application made by any unit or 
individual that possesses the conditions for exploitation, grant a CL for exploitation of an 
invention patent or utility model patent.”189 The conditionalities, which are fully laid out in the 
Chapter, are summarised as follows: 
• Article 48 (1) and (2) Failure by the patentee to fully exploit the patented right 
• Article 49 for the benefit of public health, 
• Article 51 where an invention or utility model, for which the patent right has been 
obtained, represents a major technological advancement of remarkable economic 
significance, compared with an earlier invention or utility model for which the patent 
right has already been obtained, and exploitation of the former relies on exploitation of 
the latter. 
• Article 52 If an invention involved in a compulsory license is a semi-conductor 
technology, the exploitation thereof shall be limited to the purpose of public interests; 
• Article 53 provides that compulsory license shall mainly be exercised for the supply to 
the domestic market. 
• Article 54 provides for conditionality of grant under reasonable terms 
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• Article 55 provides for the decision for granting of the compulsory license to be made 
in a timely manner and shall be registered and announced. 
It is noted for the purposes of this submission that under Article 49 for the benefit of public 
health, “a compulsory license may be granted for manufacture of the drug for which a patent 
right has been obtained or for its export to the countries or regions that conform to the 
provisions of the relevant international treaties to which the People's Republic of China has 
acceded.”190 The implementation mechanism would only be elaborated upon in amendments 
of the law and policies. 
Compulsory Licensing and the Patent Law (as amended in 1993) 
As mentioned before, the Patent Law (as amended in 1993) came about after the Sino- 
US Trade Negotiation and MOU was signed in 1992. The Standing Committee of the People’s 
Congress passed the amendment on September 4, 1992, and the amended Patent Law came 
into force on January 1, 1993. Bonin Lin et al offer that according to these amendments, 
granting of CL can now be made under more strict conditions. As a result, the Patent Law of 
1992 was not without its shortfalls. While it provided ‘stricter conditions’ for granting CLs, it 
failed to speak to abuse of dominance. Nor did it elaborate on how abuse of patents should be 
dealt with. 
Compulsory licensing and the Patent Law (as amended in 2002) 
The second amendment was intended to bring the Patent Law into compliance with the TRIPS 
Agreement. As a member of the WTO, the ensuing amendments were imperative. These took 
place after China acceded into WTO on November 12, 2001. “The amendments fell in three 
categories: (i) new judicial administrative protections, (ii) upgraded the law with international 
standards and treaties, application procedures and (iii) streamlined enforcement 
mechanisms.”191 Where CL is concerned, the Patent Law was amended to bring it in alignment 
with Article 31 of the TRIPS Agreement.  
One of the conditionalities under which a CL could be applied for are provided under 
Articles 48 (2) and 50 of the Patent Law Amendment Act. Article 48(2) provides that “where 
acts of exercising patent rights by a patentee have been determined as monopolistic acts 
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pursuant to the law, and mandatory licensing is granted to eliminate or reduce the adverse 
impact on competition caused by such act.” 
Article 50 provides that “for the purposes of public health, the patent administrative 
authorities of the State Council may grant mandatory licensing for patented drugs 
manufactured and exported to countries or regions which comply with the provisions of the 
relevant international treaty participated by the People’s Republic of China.” 
In addition, the decision is subject to judicial review if either the patentee or the licensee is 
dissatisfied with the license fee stipulated under the compulsory license. Further amendments 
to the Patent Act were elaborated upon in the Patent Act Implementing Rules (PAIR).192 
Chapter 5 deals with Compulsory Licence for exploiting a patent. Rule 73 provides: 
“The Medicine subject to patent rights in Article 50 of the Patent Law refers to any 
patented product or any product directly obtained through a patented process to resolve 
the public health issues in the medical field, including active ingredients for the 
manufacture of the product and the diagnostic apparatus required for using the 
product.” 
This was a significant change to the previous reading of Article 50. 
As part of instituting measures for implementing compulsory licensing provisions 
within this Patent Law; the State Council introduced Regulations to improve the area of 
Compulsory Licensure. This was achieved through promulgating Measures on Compulsory 
Licensing of Patents, which came into force on 15 July 2003.193 Further, to comply with the 
Doha Declaration and the WTO Council Decision on Implementation of Paragraph 6 of the 
Doha Declaration; China introduced the State Intellectual Property Office (SIPO) introduced 
“The Measure on Implementation of Compulsory License Related to Public Health Rights” 
came into effect from January 2006. According to Torremans et al, this Measure was meant to 
align with the TRIPS Agreement in the area of dependent patents and limiting of compulsory 
licensing. 
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Compulsory Licensing and the Patent Law (Amendment of 2008) 
The Patent Law was revised for the third time in 2008 and came into force on October 
1, 2009.194 In the drafting process documents, it is noted that the revised Patent Law introduced 
a number of additional grounds for granting of compulsory licenses.195 The amendment to 
Article 48(2) was such as that grant of a CL was allowed ‘in order to avoid or eliminate the 
adverse effects caused to competition in cases where it has been legally determined that the 
enforcement of the patent right by the patentee constitutes a monopolistic act.’ 
Unfortunately, these provisions alone lacked detailed implementation regulations and 
proved to be insufficient to drive a solid compulsory licensing mechanism. According to 
Buchanan et al the generic medicines generated low and the lack of specific legal standards on 
the processing of medicine compulsory license applications, stunted China’s ability to harness 
compulsory licensing of patented medicines.196 
To improve the effectiveness of the provisions, the SIPO issued Measures for 
Compulsory Licensing of Patent Implementation (Order No. 64) on 15 March 2012. These 
compulsory licensing measures were installed for patented medicines to meet public health 
needs. These Measures replaced the Measures of January 1, 2006, for Compulsory Licence on 
Patent Implementation Concerning Public Health Problems (Order No. 37).197 The move came 
just a few months after a similar move by “India to effectively end the monopoly on an 
expensive cancer drug made by Bayer AG.”198 The same CL had been issued in Malaysia, 
Indonesia and Thailand, among others.199 
The 2012 Measures provided procedural clarification to the provisions on the 
compulsory licensing mechanism as provided for in the “provisions on Compulsory Licenses,” 
which were promulgated by SIPO in 2003 and the “Measure for Compulsory License on Patent 
Implementation Concerning Public Health Problems” which was promulgated by SIPO in 
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2005. Buchanan et al support the assertion that the 2012 Measures significantly updated the 
original Measures by “standardising the scope of, application procedures for, and restrictions 
on medicine compulsory license applications”.200 
Under these implementing measures, China’s SIPO (now CNIPA) could issue and terminate 
CLs for invention patents and utility patents to a qualified entity or individual in three instances: 
1. Non-use of the patented invention or misuse of patent in violation of anti-monopoly 
law; 
2. Public welfare, including “national emergency or extraordinary situation,” “public 
interest,” and “public interest”; and 
3. Cross-licence for exploitation of an improvement invention.201 
Ming Q Lu et al document that the evolution of these measures paved the way for generic 
manufacture of more affordable medicines and essentially protects the domestic manufacturing 
market and prevent abuse from foreign manufacturers thereby facilitating the Healthy China 
2030 Programme mentioned earlier in this Chapter. 
Case studies of issuance of Compulsory licensing 
The CNIPA has yet to grant a CL. The only time China threatened to invoke a CL was 
in 2005 during an outbreak of the bird flu. The State Council through SIPO threatened Roche 
Pharma to issue a CL of its patented drug Oseltamivir (Tamiflu).202 This resulted in “Roche 
entering into voluntary agreement with two generic companies to ensure sufficient supply of 
the drug to meet the public requirements in China.”203 The decision was taken after a Chinese 
company’s application for a CL to produce a version of Roche’s Tamiflu was refused. 
In his thesis Chen highlights the challenges cited by the SIPO in issuance of CL. These 
include the complexities in the application procedure and approval timeframes by local 
manufacturers, who are expected to submit CL applications to the State Food and Drug 
Administration (SFDA) and the MoH .Then the MoH needs to apply for the licence from the 
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SIPO, with a convincing case of how the licence will lead to the promotion of a public health 
goal.204  
Despite numerous calls for the government of China to issue medicinal product CL, 
these have never been approved. Chen highlights the procedural complexities inherent in the 
applicability of the system despite the CL Measures. These include the legal reasons that have 
to be forwarded by the applicant for a CL, which should include the fact that there is clear anti- 
competitive conduct; a national emergency situation and the threat to public interests.205 While 
the number of patients with Hepatitis B, HIV/AIDS and cancers remains large in China, the 
question of whether these numbers amount to a “public health crisis” is one that has never been 
answered by the SIPO.  
Chen is of the opinion that the State Council’s main concerns are said to only “consider 
the foreign pharmaceuticals investment interests”.206 He is also of the view that in order to 
advance this debate, circumstances of “where the national emergency occurs and where the 
public interest requires” need further clarification, including allowing the exception of applying 
for CLs for the public health interests, such as the rising cancer burden. He further submits that 
in order to operationalise the CL implementation measures, the channels for patients to appeal 
their need should be established as well and the government should take the applications 
seriously on making the decision.207 
So far China has used the threat of compulsory licensing for anti-competitive behaviour. 
In 2017, China published its 2nd version of the Draft Anti-Monopoly Guidelines on the Abuse 
of Intellectual Property Rights to improve the implementation of the Anti-Monopoly Law of 
the People’s Republic of China (AML) of 2007.208 Bush offers that the final text of the AML 
sheds little light on the authorities’ approach to licensing restrictions, including on compulsory 
licensing as a remedy for abusive conduct.209 Article 55 of the AML provides that “the AML 
is not applicable to the exercise of intellectual property rights by undertakings in accordance 
with laws and administrative regulations on intellectual property rights; however, the AML 
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shall be applicable to conducts of undertakings that eliminate or restrict competition by abusing 
intellectual property rights.”210 
Conclusion 
From this Chapter, it is apparent that China has made strides to improve the 
applicability of China’s CL mechanism. Throughout its various patent law reforms, the country 
has taken extensive steps to adapt a CL mechanism to be aligned with the TRIPS Agreement. 
The articulation of administrative Measures for Compulsory Licensing of Patent 
Implementation from 2002 to those of 2012 have been improved to incorporate parameters 
concerning public health concerns. This is clear evidence that the aim of these reforms is to 
standardise the scope and applications of medicine CL applications. From Chen’s analysis, 
even with these reforms, market forces threaten the use of CL Measures. Like South Africa, 
the current system remains cumbersome and administratively heavy, resulting in its 
effectiveness being questioned. As it stands, China leverages on the AML to remedy anti- 
competitive behaviour even in the area of pharmaceutical products. As at the time of writing, 
there had not been a single case or administrative decision dealing directly with CL even 
through application of the Anti-Monopoly Law. This is different from the South African 
scenario, where the Competition law has been leveraged as the entry point where abuse of 
patent rights is concerned. From this case study, it is apparent that while the PRC has tried to 
further clarify the applicability of its compulsory licensing mechanisms through the 
Implementing Measures, this has not necessarily resulted in a reduction in the price of essential 
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Chapter 5: Conclusion and Recommendations 
Over the last three decades countries have struggled to ensure sustainable access to 
affordable innovative pharmaceutical commodities, including diagnostic tools and affordable, 
less toxic treatments. 18 years post-Doha and WTO member states are face challenges in 
navigating high medicine prices while having to respond to mushrooming communicable and 
non-communicable disease burdens which require newer treatment options. Countries have 
adopted numerous medicines pricing strategies and policies, such as the Single Exit Price (SEP) 
mechanism in South Africa. Yet, the battle to find a balance between catalysing innovations 
through the patent system and trying to regulate excessively pricing of pharmaceutical products 
continues. 
South Africa struggles to leverage its CL mechanism to remedy instances of abuse of 
patents rights and to circumvent anti-competitive behaviour where medicines’ pricing is 
concerned. The way in which the CL provision was design renders it impractical. Competition 
law is the preferred policy option to address anti-competitive behaviour. Voluntary licenses are 
also seen as viable options to secure newer medicines but these are inadequate. These licences 
are few and far in-between and are often only available to certain geographical locales 
depending in the licence agreements signed with multinational companies. 
This purpose of this minor dissertation was to offer a comparative evaluation of the 
treatment of CL in the Russian Federation and the People’s Republic of China. The aim was to 
assess whether South Africa – which is embarking on a reform path – can distil some practical 
lessons in the policy approaches taken by these counterparts. Of interest, was to assess the 
feasibility of a CL measure that could also be a cost-containment tool to respond to price 
dominance in essential pharmaceutical commodities. 
Chapter 3 evaluated the Russian Republic as a case study. It provide an overview of the 
public health reforms that took place after the collapse of the Soviet Union. The need to 
standardise the health care system led to the restructuring of its healthcare policies and 
governance structures. These plans all ensured that  the country’s health policies contributed 
towards establishing a people-centred public health system. This Health 2020 Agenda plan was 
launched tin 2016 to drive the country’s aspirations for local production of innovative 
medicines and to support efforts to strengthen IP protection and enforcement. 
Concurrent to these public health policy reforms was the transformation of the IPR legal 
and policy landscape. The former IP laws were reformed and adapted in order to ensure 
alignment with the TRIPS Agreement. Three critical periods of radical IP transformation were 
documented between 1992 and 2008, after the passage of the first iteration of the Civil Code. 
These led to a reform IPRs landscaped. Even with the changes to its IP regime, Russia has often 
been criticised for having weak enforcement regulations and systems. This is also the case in 
the operationalisation of its CL mechanism, as articulated under Articles 1360 and 1362 of the 
Russian Civil Code. The process to grant CL remains judicial and not favourable to those who 
wish to exploit the mechanism. Most multinational corporates are protected by the ‘anti-trust 
immunity’ provisions offered under the country’s Competition Law. This presents further 
barrier when parties wish to challenge the validity and fairness of patents held by these 
corporations over essential pharmaceuticals. 
The Russian Ministry of Health’s Federal Anti-Monopoly Service (FAS) has tabled a 
few proposals, each proposition policy options for the expansion of CL as a cost containment 
tool. These proposals have been contested by both government and industry, primarily because 
they are seen as a threat to foreign direct investment in Russia. The FAS wishes to leverage on 
CL to curtail the abuse of exclusive patent rights and to be an instrument to respond to national 
public health emergencies. The most recent proposal was tabled in November 2019.  
Russia hopes to implement the “Roadmap for Development of Competition in 
Healthcare” – a strategy that has been implemented since 2018. This Roadmap identifies 
critical areas to advance health care reform; including the development of procedures for 
implementation of CL in line with the proposals tabled by the FAS. 
Chapter 4 focused on China as a case study. The offering documented this country’s 
aggressive approach to transform its public health sector. The move resulted in China’s 
decentralised tiered system being transformed into a profit-driven market-centric system. 
Firstly, these reforms replaced with access to free healthcare with a privatised system. 
Secondly, the new system has stunted primary healthcare by prioritising a more centralised 
system. This has increased the health care access gap, a challenge the country is trying to 
remedy with numerous experimental policies.  
China’s IPR and patent laws were reformed to fulfil its obligations under the TRIPS 
Agreement. The CL policy approaches have included the adoption of a series of 
Implementation Measures for the grant of CL. The most recent amendment being in 2012. 
These Measures incorporated procedural clarification to the CL provisions within the Patent 
Act. 
Parallel to these legal reforms, the State Council launched the NIPS in 2008, followed 
by the National IP Strategy Action Plan (2014-2020) in 2014. The former was to formulate 
reasonable and relevant policies to incubate and strengthen the country’s nascent 
pharmaceutical industry. The latter was an in-depth action plan to ensure that the NIP was 
effectively implemented. China’s Patent Act is undergoing its fourth amendment, which is 
expected to be promulgated in 2020. 
What remains unclear in the Chinese case study is how the wave of new policies and 
implementing measures continue to have limited procedural applicability. It is observed that 
the country’s intellectual property system has changed from actively transplanting laws from 
abroad to introducing amendments that are specifically tailored to rapidly changing domestic 
context. Given China’s ascendancy in the international trade area, the government believes that 
policy preparedness is a critical pre-emptive strategy. China wishes to build a flourishing local 
manufacturing industry supported by a solid research and development (R&D) base to ensure 
innovations in pharmaceuticals, instead of a generic industry. As a results, its IRP landscape 
and related policies all work towards supporting this national prerogative. 
In summary, both jurisdictions have taken extensive steps to reforming their entire IPR 
landscapes to ensure that their IPR and patent landscapes respond to their development 
aspirations, while navigating the demands of the international trade system. The approaches 
taken by both countries have been different. China undertaking a more internalized approach 
in its IPR policies to catalyse innovations in its local pharmaceutical industry. While the 
country has installed CL Measures, these do not seem to be prioritised as cost-containment 
measures. Russia on the other hand has taken an insulated and responsive approach, 
experimenting with proposals to design an appropriate CL mechanism that will both act as a 
cost-containment measure to curtail price dominance by multinational corporations. In 
regulating prohibitive pharmaceutical prices, China does provide for CL to curb abuse of 
patents but has so far relied on its Anti-Monopoly Law. Russia continues to struggle in its 
plight to find a balance between regulating the abuse of patents, which is not provide for in its 
patent law and the “anti-trust immunity” provisions that its competition law offers to 
multinational corporation, which seems to defeat the goals of trying to circumvent anti-
competitive behaviour. What is observed about these two jurisdictions is that none of their CL 
mechanisms truly operate as cost-containment alternatives.  
Recommendations 
This thesis offers the following recommendations for the South Africa CL reform 
pathway. 
Firstly, the government could benefit from conceptualising a clear policy position on 
the kind of CL mechanism it required for the country’s development prerogative, as it 
transitions from being extractive-dependent to a knowledge economy which supports 
innovation, technology transfer, research and development (R&D) and industrial development.  
It is unclear whether the national IP policy envisages that the procedure for grant of CL 
remains adjudicative with a few amendments or it wishes to  transform it into an administrative 
system of application. Or a merger of the two. For the former, legal reform of the current 
provisions would be required to install a more flexible grant adjunctive process. The latter 
would require consideration into feasible systematics to regulate and operationalise the CL 
mechanism.  
Secondly, there is need to clarify and perhaps expand on the grounds of CL grant. This 
will assist in clarifying if SA remains with the grounds of CL grant as listed in the Patents Act 
or if these need to be strengthened and streamlined to meet the country’s development 
objectives. For example, this thesis assumes that excessive prices in innovative medicines is an 
abuse of patent rights and therefore “anti- competitive”. So far, the CCSA has undertaken 
numerous cases dealing with abuse of patents where pricing is concerned. Therefore, a clear 
policy position would assist to distil the relationship between the two pieces of legislation. 
Thirdly, the government could follow a similar model to China and install separate CL 
Implementation Measures to guide the implementation of the CLs. This could be a temporary 
solution as the government engages in extensive negotiations to amend its IPR landscape and 
as it considers the policy proposals that will debated to effect IPR legal reform. The long term 
view being that these will assist as ‘pilots’ to inform the establishment of a ‘workable CL 
system’. 
Since the adoption of the national IP Policy in 2018, the country has not taken any next steps 
to provide policy guidance on the reform model it will engage in.  
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